2019 Prior Authorization (PA) Criteria

Certain drugs require prior authorization from ConnectiCare Medicare Advantage Plans. This means that your doctor must contact us to get approval before prescribing the drug to you. If your doctor does not get prior approval, the drug may not be covered.

This list also includes drugs that may be covered under Medicare Part B or Part D depending on how the drugs are used or administered. If your drug is on this list, your doctor should call us and provide information describing the use and administration of the drug so we can advise on whether the drug will be covered.

To see if your drug is on the list, refer to the index located at the end of this document for the medication you are looking for or click this [SEARCH] button and enter the name of your drug in the pop-up task pane.

ConnectiCare

ACTHAR

Products Affected

- Acthar H.P.

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Use in patients with multiple sclerosis (MS) as pulse therapy on a monthly basis. Use as maintenance therapy in patients with psoriatic arthritis, rheumatoid arthritis, or ankylosing spondylitis. Treatment of proteinuria in diabetic nephropathy.
Required Medical Information	MS exacerbation, rheumatic disorder exacerbation, history of corticosteroid use
Age Restrictions	N/A
Prescriber Restrictions	Infantile spasms, prescribed by or in consultation with a neurologist or an epileptologist. MS exacerbation, prescribed by or in consultation with a neurologist or physician that specializes in the treatment of MS. Rheumatic disorder exacerbation, prescribed by or in consultation with a rheumatologist.
Coverage Duration	One month
Other Criteria	For MS exacerbation and rheumatic disorder exacerbation, approve if the patient cannot use high-dose IV corticosteroids because IV access is not possible or if the patient has tried high-dose corticosteroids administered IV for an acute exacerbation and has experienced a severe or limiting adverse effect.

ACTIMMUNE

Products Affected

- Actimmune

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

ADCIRCA

Products Affected

- Adcirca

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Nitrate therapy
Required Medical Information	PAH been confirmed by right heart catheterization.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

ADEMPAS

Products Affected

- Adempas

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	PAH and CTEPH- must be prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	12 months
Other Criteria	For PAH - must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1). Right heart catheterization is not required in pts who are currently receiving Adempas or another agent indicated for WHO group 1.

ConnectiCare

AFINITOR

Products Affected

- Afinitor
- Afinitor Disperz

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist or a Neurologist.
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

ALECENSA

Products Affected

- Alecensa

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Patients already started on Alecensa for a covered use
Exclusion Criteria	N/A
Required Medical Information	Confirmed ALK-positive NSCLC as detected by an FDA-approved test and prior therapies tried
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	Anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC): The patient has metastatic ALK-positive NSCLC as detected by an FDA-approved test AND The patient has progressed on or are intolerant to Xalkori (crizotinib)

ConnectiCare

ALOSETRON

Products Affected

- alosetron

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D coverage
Exclusion Criteria	Patient has a history of any of the following conditions: Chronic or severe constipation or sequelae from constipation. Intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions. Ischemic colitis. Impaired intestinal circulation, thrombophlebitis or hypercoagulable state. Crohn's disease or ulcerative colitis. Diverticulitis. Severe hepatic impairment.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For diagnosis of severe diarrhea-predominant irritable bowel syndrome (IBS) alosetron is being prescribed for a woman AND chronic IBS symptoms have lasted at least 6 months AND gastrointestinal tract abnormalities have been ruled out AND the patient has had inadequate response to conventional therapy.

ConnectiCare

ALUNBRIG

Products Affected

- Alunbrig oral tablet 180 mg, 30 mg, 90 mg
- Alunbrig oral tablets,dose pack

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Concurrent use with other chemotherapy, patients with ALK-negative NSCLC, pediatric patients less than 18 years of age
Required Medical Information	Diagnosis, prior therapies, ALK-positive NSCLC confirmed by an FDA-approved test
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	For NSCLC, patient has metastatic or recurrent disease that is ALK-positive as detected by an FDA-approved test AND patient has progressed on Xalkori (crizotinib)

ConnectiCare

AMPYRA

Products Affected

- Ampyra

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus patient already started on dalfampridine extended-release for Multiple Sclerosis (MS).
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	MS. If prescribed by, or in consultation with, a neurologist or MS specialist.
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

ANADROL

Products Affected

- Anadrol-50

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

ANTICONVULSANTS

Products Affected

- topiramate oral capsule, sprinkle
- topiramate oral capsule,sprinkle,ER 24hr
- topiramate oral tablet
- zonisamide

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

APOKYN

Products Affected

- APOKYN

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

APTIOM

Products Affected
- Aptiom

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

ARCALYST

Products Affected

- Arcalyst

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus patient already started on rilonacept for Muckle Wells Syndrome (MWS) or Familial Cold Autoinflammatory Syndrome (FCAS).
Exclusion Criteria	Rilonacept should not be given in combination with biologic therapy (e.g. tumor necrosis factor (TNF) blocking agents (eg, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), anakinra, or canakinumab).
Required Medical Information	N/A
Age Restrictions	Initial tx CAPS-Greater than or equal to 12 years of age.
Prescriber Restrictions	Initial tx CAPS-prescribed by, or in consultation with, a rheumatologist, geneticist, dermatologist or immunologist.
Coverage Duration	12 months
Other Criteria	CAPS renewal - approve if they have had a response and are continuing therapy to maintain response/remission.

ConnectiCare

AURYXIA

Products Affected

- Auryxia

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

AVONEX

Products Affected

- Avonex (with albumin)
- Avonex intramuscular pen injector kit
- Avonex intramuscular syringe kit

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Concurrent use of other disease-modifying agents used for multiple sclerosis (MS)
Required Medical Information	Multiple Sclerosis (MS) diagnosis worded or described as patients with a diagnosis of MS or have experienced an attack and who are at risk of MS.
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, a neurologist or physician who specializes in the treatment of MS.
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

BANZEL

Products Affected

- Banzel

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

BENLYSTA

Products Affected

- Benlysta subcutaneous

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Patients with severe lupus nephritis or severe active central nervous system lupus, concurrent use with other biologics or intravenous cyclophosphamide
Required Medical Information	Diagnosis, patient has active, autoantibody-positive, systemic lupus erythematosus and is receiving standard therapy
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with, a rheumatologist, or a physician that specializes in diseases of joints and muscles
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

BETASERON

Products Affected

- Betaseron subcutaneous kit

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use of other disease-modifying agents used for multiple sclerosis (MS)
Required Medical Information	Multiple Sclerosis (MS) diagnosis worded or described as patients with a diagnosis of MS or have experienced an attack and who are at risk of MS.
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, a neurologist or physician who specializes in the treatment of MS.
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

BEXAROTENE

Products Affected

- bexarotene

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis, prior therapies tried.
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	Patient has been instructed on the importance of and proper utilization of contraception. For primary cutaneous T cell lymphoma, patient is refractory to one prior systemic therapy.

ConnectiCare

BOSULIF

Products Affected

- Bosulif

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Bosulif for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which Bosulif is being used. For chronic myelogenous leukemia (CML), the Philadelphia chromosome (Ph) status of the leukemia must be reported. For CML, prior therapies tried must be reported to confirm resistance or intolerance.
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For Chronic phase, accelerated phase (AP), or blast phase (BP) Ph+ CML, must have resistance or intolerance to any one prior therapy for approval.

ConnectiCare

BRIVIACT

Products Affected
- Briviact oral

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

CABOMETYX

Products Affected

- Cabometyx

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of advanced renal cell carcinoma, medication history, histology
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

CALQUENCE

Products Affected
- Calquence

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Previous treatment with a BTK inhibitor (e.g. Imbruvica)
Required Medical Information	Diagnosis, previous therapies tried
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with, an oncologist
Coverage Duration	12 months
Other Criteria	For mantle cell lymphoma (MCL), patient has received at least one prior therapy

ConnectiCare

CHOLBAM

Products Affected

- Cholbam

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	baseline liver function tests
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with hepatologist, metabolic specialist, or GI
Coverage Duration	Initial approval for 3 months, continuation approval for 12 months
Other Criteria	For continuation of therapy to be approved patient must meet 2 of the 3 following lab criteria or meet 1 of the 3 follow lab criteria and have body weight increased by 10% or stable at greater than the 50th percentile. Lab criteria: (1) patient alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 50 U/L or the baseline levels reduced by 80%, (2) patient total bilirubin level must be reduced to less than or equal to 1 mg/dL, (3) patient must not have evidence of cholestasis on liver biopsy.

ConnectiCare

CIALIS

Products Affected

- Cialis oral tablet 2.5 mg, 5 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Indication for which tadalafil is being prescribed.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Benign prostatic hyperplasia (BPH), after confirmation that tadalafil is being prescribed to treat the signs and symptoms of BPH and not for the treatment of erectile dysfunction (ED) and after a trial of an alpha-1 blocker (eg, doxazosin [Cardura XL], terazosin, tamsulosin [Flomax], alfuzosin extended-release [UroXatral]) or 5 alpha reductase inhibitor (eg, finasteride, dutasteride [Avodart]).

ConnectiCare

CINRYZE

Products Affected

- Cinryze

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Must be prescribed by, or in consultation with, an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders.
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

COMETRIQ

Products Affected

- Cometriq

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Cometriq for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of progressive, metastatic medullary thyroid cancer.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

CORLANOR

Products Affected

- Corlanor

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Previous use of a Beta-blocker, LVEF, sinus rhythm, and resting HR
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	HF in pts not currently receiving Corlanor - must all of the following 1. have LVEF of less than or equal 35 percent, 2. have sinus rhythm and a resting HR of greater than or equal to 70 BPM, AND 3. tried or is currently receiving a Beta-blocker for HF (e.g., metoprolol succinate sustained-release, carvedilol, bisoprolol, carvedilol ER) unless the patient has a contraindication to the use of beta blocker therapy (e.g., bronchospastic disease such as COPD and asthma, severe hypotension or bradycardia). HF in pts currently receiving Corlanor - had a LVEF of less than or equal to 35 percent prior to initiation of Corlanor therapy AND has tried or is currently receiving a Beta-blocker for HF unless the patient has a contraindication to the use of beta blocker therapy.

ConnectiCare

COSENTYX

Products Affected

- Cosentyx (2 Syringes)
- Cosentyx Pen (2 Pens)

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
Required Medical Information	Diagnosis, concurrent medications, previous therapies tried.
Age Restrictions	18 years and older
Prescriber Restrictions	For Psoriatic Arthritis (PsA), must be prescribed by or in consultation with a dermatologist or rheumatologist. For Ankylosing Spondylitis (AS), must be prescribed by, or in consultation with, a rheumatologist. For Plaque Psoriasis (PP), must be prescribed by or in consultation with a dermatologist.
Coverage Duration	12 months
Other Criteria	For PP, approve if the patient has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant. Patients who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first.

ConnectiCare

COTELLIC

Products Affected

- Cotellic

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Presence of BRAF V600E or V600K mutation confirmed by an FDA approved test
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	Unresectable or metastatic melanoma - being prescribed in combination with vemurafenib

ConnectiCare

CRINONE

Products Affected

- Crinone

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Use in patients to supplement or replace progesterone in the management of infertility.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Secondary amenorrhea, 12 months. Support of an established pregnancy, 9 months.
Other Criteria	N/A

ConnectiCare

DARAPRIM

Products Affected

- Daraprim

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D
Exclusion Criteria	hypersensitivity to pyrimethamine, documented megaloblastic anemia due to folate deficiency
Required Medical Information	Medication history, patient's immune status
Age Restrictions	N/A
Prescriber Restrictions	Toxoplasma gondii Encephalitis, Chronic Maintenance and Prophylaxis (Primary)-prescribed by or in consultation with an infectious diseases specialist. Toxoplasmosis Treatment-prescribed by or in consultation with an infectious diseases specialist, a maternal-fetal medicine specialist, or an ophthalmologist.
Coverage Duration	12 months
Other Criteria	Malaria Prophylaxis, approve if the patient has tried at least two other antimalarials (eg, atovaquone-proguanil, chloroquine phosphate, hydroxychloroquine sulfate, doxycycline, mefloquine, and primaquine). Malaria Treatment, approve if the patient has tried at least two other antimalarials (eg, Coartem [artemether-lumefantrine tablets], quinine sulfate or quinidine gluconate in combination with doxycycline, tetracycline, or clindamycin, quinine sulfate in combination with primaquine and either doxycycline or tetracycline, or the following medications as monotherapy or in combination with primaquine: atovaquone-proguanil, mefloquine, chloroquine phosphate, and hydroxychloroquine). Toxoplasma gondii Encephalitis, Chronic Maintenance, approve if the patient is immunosuppressed. Toxoplasma gondii Encephalitis Prophylaxis (Primary), approve if the patient is immunosuppressed and the patient has tried one other recommended therapy, unless contraindicated (eg, trimethoprim-sulfamethoxazole [TMP-SMX], atovaquone).

ConnectiCare

DEMSER

Products Affected

- Demser

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

DICLOFENAC GEL

Products Affected

- diclofenac sodium topical gel 3 %

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

DIGOXIN

Products Affected

- Digitek
- Digox
- digoxin oral solution 50 mcg/mL
- digoxin oral tablet
- Lanoxin oral tablet 125 mcg, 250 mcg, 62.5 mcg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D coverage
Exclusion Criteria	N/A
Required Medical Information	The physician has documented the indication for the continued use of the HRM (high risk medication) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed digoxin 0.125mg daily or provided clinical rationale as to why the lower dose is not appropriate for the patient.
Age Restrictions	This prior authorization only applies to members 65 years of age or older to ensure safe use of a potentially high risk medication in the elderly population. Members under 65 years of age are not subject to the prior authorization requirements.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

DUPIXENT

Products Affected

- Dupixent subcutaneous syringe 300 mg/2 mL

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Treatment naive patients
Required Medical Information	Diagnosis, previous therapies tried and lengths of trials, percentage of body surface area affected
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with, an allergist, immunologist, or dermatologist.
Coverage Duration	Initiation 16 weeks, Continuation 12 months
Other Criteria	Initial therapy patient has atopic dermatitis involvement estimated to be over 10% of the body surface area (BSA), AND patient has used at least one medium, medium-high, high, and/or super-high-potency prescription topical corticosteroid for at least 30 consecutive days AND the patient has tried tacrolimus ointment for at least 30 consecutive days AND inadequate efficacy was demonstrated with topical therapy, according to the prescribing physician. Continuation Approve if the patient has responded to Dupixent therapy as determined by the prescribing physician (e.g., marked improvements in erythema, induration,papulation,edema, excoriations, and lichenification, reduced pruritus, decreased requirement for other topical or systemic therapies, reduced body surface area (BSA) affected with atopic dermatitis, or other responses observed).

ConnectiCare

EGRIFTA

Products Affected

- Egrifta subcutaneous recon soln 1 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis.
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or a physician specializing in the treatment of HIV (eg, infectious disease, oncology).
Coverage Duration	12 months
Other Criteria	HIV-infected adult patients (18 years of age or older) with lipodystrophy AND Egrifta is being used to reduce excessive abdominal fat

ConnectiCare

ENBREL

Products Affected

- Enbrel subcutaneous recon soln
- Enbrel subcutaneous syringe 25 mg/0.5mL (0.51), 50 mg/mL (0.98 mL)
- Enbrel SureClick

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
Required Medical Information	Diagnosis, concurrent medications, previous therapies tried.
Age Restrictions	Juvenile idiopathic arthritis (JIA)- 2 years or older. Plaque psoriasis (PP)- 4 years or older. Ankylosing spondylitis (AS), Psoriatic arthritis (PsA), Rheumatoid arthritis (RA)- 18 years and older.
Prescriber Restrictions	For RA, AS, and JIA, must be prescribed by, or in consultation with, a rheumatologist. PsA, must be prescribed by, or in consultation with, a rheumatologist or dermatologist. PP, must be prescribed by, or in consultation with, a dermatologist.
Coverage Duration	12 months
Other Criteria	For RA, patient has tried one conventional synthetic DMARD for at least 3 months. Patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD. For JIA, approve if the patient has aggressive disease or the patient has tried one other agent for this condition (eg, MTX, sulfasalazine, leflunomide, NSAID, biologic DMARD) or the patient will be started on Enbrel concurrently with MTX, sulfasalazine, or leflunomide. For PP, approve if the patient meets one of the following conditions: 1) patient has tried at least one traditional systemic agent for at least 3 months for plaque psoriasis, unless intolerant (eg, MTX, cyclosporine, Soriatane, oral methoxsalen plus PUVA). Patients who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first.

ConnectiCare

ENDARI

Products Affected

- Endari

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	5 years of age and older
Prescriber Restrictions	Prescribed by, or in consultation with, a physician who specializes in SCD (e.g., a hematologist).
Coverage Duration	12 months
Other Criteria	For Sickle Cell Disease, patient will be using Endari to reduce acute complications.

ConnectiCare

EPCLUSA

Products Affected

- Epclusa

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Combination use with other direct acting antivirals, excluding ribavirin.
Required Medical Information	Documentation from the medical record of diagnosis including genotype, HCV RNA viral levels prior to treatment, history of previous HCV therapies, and presence/absence of cirrhosis. For patients with cirrhosis, cirrhosis must be documented by FibroScan, FibroTest ActiTest, liver biopsy, or radiological imaging.
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician.
Coverage Duration	12 weeks, based on indication and current AASLD/IDSA guidance.
Other Criteria	Criteria will be applied consistent with current AASLD/IDSA guidance

ConnectiCare

ERIVEDGE

Products Affected

- Erivedge

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus, patient already started on Erivedge for a covered use.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	Metastatic or Locally advanced basal cell carcinoma (LABCC), approve if the patients BCC has recurred following surgery or the patient is not a candidate for surgery or radiation therapy.

ConnectiCare

ERLEADA

Products Affected

- Erleada

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Pregnancy
Required Medical Information	Documentation from medical records of diagnosis. For non-metastatic castration-resistant prostate cancer, prior therapies tried.
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For prostate cancer, patient must have non-metastatic, castration-resistant prostate cancer for approval. Patient must be receiving Erleada in combination with a gonadotropin-releasing hormone (GnRH) analog OR had a bilateral orchiectomy.

ConnectiCare

ESBRIET

Products Affected

- Esbriet

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Combination use with Nintedanib
Required Medical Information	N/A
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in combination with a pulmonologist
Coverage Duration	12 months
Other Criteria	IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP.

ConnectiCare

EXTAVIA

Products Affected

- Extavia subcutaneous kit

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Concurrent use of other disease-modifying agents used for multiple sclerosis (MS)
Required Medical Information	Multiple Sclerosis (MS) diagnosis worded or described as patients with a diagnosis of MS or have experienced an attack and who are at risk of MS.
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, a neurologist or physician who specializes in the treatment of MS.
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

FARYDAK

Products Affected

- Farydak

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	History of previous therapies tried
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist or Hematologist
Coverage Duration	12 months
Other Criteria	Must be used in combination with Velcade and dexamethasone AND previously tried Velcade and one immunomodulatory drug (i.e., Thalomid, Revlimid, or Pomalyst).

ConnectiCare

FERRIPROX

Products Affected

- Ferriprox oral tablet

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

FIRAZYR

Products Affected

- Firazyr

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders.
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

FYCOMPA

Products Affected

- Fycompa oral suspension
- Fycompa oral tablet

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, a Neurologist
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

GATTEX

Products Affected

- Gattex 30-Vial

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

GILOTRIF

Products Affected

- Gilotrif

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	For metastatic non-small cell lung cancer (NSCLC) documentation of non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. For metastatic squamous NSCLC, documentation of prior platinum-based chemotherapy.
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

GLATOPA/GLATIRAMER

Products Affected

- glatiramer
- Glatopa

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use of any of the following medications: Interferon-beta therapy (Avonex, Betaseron, Extavia, or Rebif), mitoxantrone, fingolimod, teriflunomide, or dimethyl fumarate.
Required Medical Information	Previous therapies tried. Multiple Sclerosis (MS) diagnosis worded or described as patients with a diagnosis of MS or have experienced an attack and who are at risk of MS.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, a neurologist or physician who specializes in the treatment of MS.
Coverage Duration	12 months
Other Criteria	Patients with previous use (12 or more months) of Glatopa/glatiramer must demonstrate one of the following clinical responses: decrease in the frequency of relapses, slowing of disease progression, diminished MRI lesions, OR patient is stable on therapy.

ConnectiCare

GROWTH HORMONE

Products Affected

- Norditropin FlexPro

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	For pediatric GHD in neonate with hypoglycemia: patient has a randomly assessed GH level less than 20 ng/mL, other causes of hypoglycemia have been ruled out, and other treatments have been ineffective. For all pediatric patients: patients have short stature or slow growth velocity and have been evaluated for other causes of growth failure. For pediatric GHD, patient has delayed bone age. For pediatric GHD without pituitary disease, patient failed 2 stimulation tests. For pediatric GHD with a pituitary or CNS disorder, patient has clinical evidence of GHD and low IGF-1/IGFBP3. For TS and SHOX patients: diagnosis confirmed by genetic testing. For CRI patients: metabolic, endocrine and nutritional abnormalities have been treated or stabilized and patient has not had a kidney transplant. For SGA: patient has a low birth weight or length for gestational age. For ISS: pediatric GHD has been ruled out with one stimulation test. For adult GHD, patient was assessed for other causes of GHD-like symptoms. For adult GHD without pituitary disease, patient failed 2 stimulation tests. For adult GHD with at least 3 pituitary hormone deficiencies (PHD) or panhypopituitarism: have a low IGF-1. For adult GHD with less than 3 PHD, low IGF-1 and failed one stimulation test. For renewal: patient has seen clinical improvement.
Age Restrictions	For Turner syndrome and SGA, 2 years of age and older. For Noonan syndrome and SHOX, 3 years of age and older.
Prescriber Restrictions	Endocrinologist, Pediatric Nephrologist, Gastroenterologist, Nutritional Support Specialist, Infectious Disease Specialist
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

HARVONI

Products Affected

- Harvoni

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Combination use with other direct acting antivirals, excluding ribavirin.
Required Medical Information	Documentation from the medical record of diagnosis including genotype, HCV RNA viral levels prior to treatment, history of previous HCV therapies, and presence/absence of cirrhosis. For patients with cirrhosis, cirrhosis must be documented by FibroScan, FibroTest ActiTest, liver biopsy, or radiological imaging.
Age Restrictions	12 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician.
Coverage Duration	12 to 24 weeks, based on indication and current AASLD/IDSA guidance.
Other Criteria	Criteria will be applied consistent with current AASLD/IDSA guidance

ConnectiCare

HETLIOZ

Products Affected

- Hetlioz

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For the indication of Non-24-Hour Sleep-Wake Disorder (Non-24), approval will only be granted for patients who are totally blind.

ConnectiCare

HRM

Products Affected

- benztropine oral
- butalbital-acetaminop-caf-cod
- butalbital-acetaminophen oral tablet 50-325 mg
- butalbital-acetaminophen-caff oral capsule
- butalbital-acetaminophen-caff oral tablet 50-325-40 mg
- butalbital-aspirin-caffeine oral capsule
- clemastine oral tablet 2.68 mg
- cyclobenzaprine oral tablet
- cyproheptadine
- ergoloid
- meprobamate
- metaxalone
- methyldopa-hydrochlorothiazide
- promethazine oral tablet
- trihexyphenidyl

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve when the provider has assessed the risk versus benefit in using this High Risk Medication (HRM) in the patient and has confirmed that they would still like to initiate or continue therapy

ConnectiCare

HRM - BENZODIAZEPINES

Products Affected

- alprazolam oral tablet extended release 24 hr
- lorazepam oral
- oxazepam
- temazepam

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	Procedure-related sedation = 1mo. All other conditions = 12 months
Other Criteria	All medically accepted indications other than insomnia, authorize use. Insomnia, approve lorazepam, oxazepam, or temazepam if the patient has had a trial with two of the following: ramelteon, trazodone, doxepin 3mg or 6 mg, eszopiclone, zolpidem, or zaleplon.

ConnectiCare

HRM BENZODIAZEPINES/ANTICONVULSANTS

Products Affected

- clonazepam oral tablet,disintegrating
- clorazepate dipotassium
- Diazepam Intensol
- diazepam oral solution 5 mg/5 mL (1 mg/mL)
- diazepam oral tablet

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve when the provider has assessed the risk versus benefit in using this High Risk Medication (HRM) in the patient and has confirmed that they would still like to initiate or continue therapy

ConnectiCare

HRM PD

Products Affected

- amitriptyline
- clomipramine
- doxepin oral
- estradiol oral
- imipramine HCl
- imipramine pamoate
- megestrol oral tablet
- perphenazine-amitriptyline
- phenobarbital
- trimipramine

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve when the provider has assessed the risk versus benefit in using this High Risk Medication (HRM) in the patient and has confirmed that they would still like to initiate or continue therapy

ConnectiCare

HUMIRA

Products Affected

- Humira
- Humira Pediatric Crohn's Start subcutaneous syringe kit 40 mg/0.8 mL, 40 mg/0.8 mL (6 pack), 80 mg/0.8 mL, 80 mg/0.8 mL-40 mg/0.4 mL
- Humira Pen
- Humira Pen Crohn's-UC-HS Start subcutaneous pen injector kit 40 mg/0.8 mL, 80 mg/0.8 mL
- Humira Pen Psoriasis-Uveitis subcutaneous pen injector kit 40 mg/0.8 mL, 80 mg/0.8 mL-40 mg/0.4 mL

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
Required Medical Information	Diagnosis, concurrent medications, previous therapies tried.
Age Restrictions	Crohn's disease (CD)- 6 years or older. Juvenile idiopathic arthritis (JIA), Uveitis - 2 years or older. Hidradenitis suppurativa (HS) - 12 years or older. Ulcerative colitis (UC), Ankylosing spondylitis (AS), Plaque psoriasis (PP), Psoriatic arthritis (PsA), Rheumatoid arthritis (RA) - 18 years and older.
Prescriber Restrictions	For RA, JIA, and AS, must be prescribed by, or in consultation with, a rheumatologist. For PsA, must be prescribed by, or in consultation with, a rheumatologist or dermatologist. For PP and HS, must be prescribed by, or in consultation with, a dermatologist. UC and CD, must be prescribed by, or in consultation with, a gastroenterologist. For UV, must be prescribed by, or in consultation with, an ophthalmologist.
Coverage Duration	12 months
Other Criteria	For RA, patient has tried one conventional synthetic DMARD for at least 3 months. Patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD. For JIA, patient has tried another agent (e.g MTX, sulfasalazine, leflunomide, NSAID, or biologic DMARD) or will be starting on Humira concurrently with MTX, sulfasalazine, or leflunomide or if patient has aggressive disease. For PP, approve if the patient has tried at least one traditional

PA Criteria	Criteria Details
	systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant. Patients who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first. For CD, approve if patient has tried corticosteroids (CS) or if patient is currently on CS or if patient has tried one other agent for CD (eg, azathioprine, 6-mercaptopurine, MTX, infliximab, or ustekinumab) or patient had ilecolonic resection or enterocutaneous (perianal or abdominal) or rectovaginal fistulas. For UC, patient has tried a systemic therapy (eg, 6-mercaptopurine, azathioprine, CSA, tacrolimus, infliximab or a corticosteroid such as prednisone or methylprednisolone) for 2 months or was intolerant to one of these agents, or the patient has pouchitis and has tried therapy with an antibiotic, probiotic, corticosteroid enema, or mesalamine enema. For HS, patient has tried one other therapy (e.g., intralesional or oral corticosteroids, systemic antibiotics, isotretinoin). Clinical criteria incorporated into the Humira quantity limit edit, approve additional quantity (to allow for 40 mg every week) if the patient has a diagnosis of HS OR a diagnosis of RA in patients not receiving concomitant methotrexate.

ConnectiCare

IBRANCE

Products Affected

- Ibrance

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of HER2-negative, hormone receptor-positive, advanced or metastatic breast cancer
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For HER2-negative, hormone receptor-positive, advanced or metastatic breast cancer, must be used in combination with fulvestrant for progression following endocrine therapy OR in postmenopausal women as initial therapy in combination with an aromatase inhibitor.

ConnectiCare

ICLUSIG

Products Affected

- Iclusig

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis the Philadelphia chromosome (Ph) status of the leukemia must be reported. T315I status
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	CML T315I-positive or has tried TWO other TKIs indicated for use in CML (e.g., imatinib, Sprycel, Tasigna). ALL Ph+, T315I-positive or has tried TWO other TKIs indicated for use in Ph+ ALL (e.g. imatinib, Sprycel).

ConnectiCare

IDHIFA

Products Affected

- Idhifa

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Acute myeloid leukemia without the presence of the isocitrate dehydrogenase-2 (IDH2) mutation
Required Medical Information	Diagnosis, documentation of the presence of the isocitrate dehydrogenase-2 (IDH2) mutation in the blood or bone marrow as detected by an FDA-approved test
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with, an oncologist
Coverage Duration	12 months
Other Criteria	For relapsed or refractory acute myeloid leukemia, patient has the isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test

ConnectiCare

IMATINIB

Products Affected

- imatinib oral tablet 100 mg, 400 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) must be positive for the Philadelphia chromosome or BCR-ABL gene. For CML, patient meets one of the following: 1) newly diagnosed, 2) resistance or intolerance to prior therapy, or 3) recurrence after stem cell transplant. For ALL, patient meets one of the following: 1) newly diagnosed and imatinib is used in combination with chemotherapy, or 2) ALL is relapsed or refractory. For GIST, patient meets one of the following: 1) unresectable, recurrent, or metastatic disease, or 2) use of imatinib for adjuvant therapy following resection, or 3) use of imatinib for pre-operative therapy and patient is at risk for significant surgical morbidity.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

IMBRUVICA

Products Affected

- Imbruvica

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	For patients with mantle cell lymphoma (MCL)-history of prior treatment. For patients with marginal zone lymphoma-history of prior treatment with at least one anti-CD20-based therapy.
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist or a transplant specialist.
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

INGREZZA

Products Affected

- Ingrezza

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous therapies tried
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, a neurologist or psychiatrist
Coverage Duration	12 months
Other Criteria	Patient has a diagnosis of moderate to severe tardive dyskinesia AND a history of current or previous chronic use of an antipsychotic or other dopamine antagonist.

ConnectiCare

INLYTA

Products Affected

- Inlyta

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus, patients already started on Inlyta for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	Advanced renal cell carcinoma, approve if the patient has failed at least one prior systemic therapy (eg, Torisel, Avastin, Sutent, IFN-alpha, IL-2, Votrient, Nexavar).

ConnectiCare

IRESSA

Products Affected

- Iressa

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	Metastatic NSCLC - The patient has epidermal growth factor receptor (EGFR) exon 19 deletions OR has exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

ConnectiCare

IVIG

Products Affected

- Gammagard Liquid
- Gamunex-C injection solution 1 gram/10 mL (10 %)

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Part B versus D determination per CMS guidance to establish if drug used for PID in pts home.

ConnectiCare

JAKAFI

Products Affected

- Jakafi oral tablet 10 mg, 15 mg, 20 mg, 25 mg, 5 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus, patients already started on Jakafi for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist or Hematologist
Coverage Duration	12 months
Other Criteria	For polycythemia vera patients must have tried hydroxyurea

ConnectiCare

JUXTAPID

Products Affected

- Juxtapid

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

JYNARQUE

Products Affected

- Jynarque

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Pediatric patients less than 18 years of age, Patients with serum sodium laboratory abnormalities
Required Medical Information	Diagnosis, Serum sodium, ALT, AST and bilirubin laboratory results
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with, a nephrologist or a health care provider specializing in kidney health.
Coverage Duration	Initiation 3 months, Continuation 6 months
Other Criteria	For initiation, patient has a diagnosis of autosomal dominant polycystic kidney disease (ADPKD) AND is at risk of rapidly-progressing ADPKD. Patient has baseline serum sodium within the normal range. For continuation, patient has serum sodium laboratory results within the normal range.

ConnectiCare

KALYDECO

Products Affected
- Kalydeco

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Patients with cystic fibrosis who are homozygous for the F508del mutation in the CFTR gene.
Required Medical Information	CF mutation test documenting one mutation in the CFTR gene.
Age Restrictions	2 years of age and older for packets. 6 years of age and older for tablets.
Prescriber Restrictions	Prescribed by or inconsultation with a pulmonologist or a physician who specializes in CF
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

KEVEYIS

Products Affected
- Keveyis

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Patient with history of hypersensitivity to diclorphenamide or other sulfonamides, Patient on high dose aspirin, Patient with severe pulmonary disease, Patient with hepatic insufficiency
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial therapy - 2 months, Continuing therapy - 12 months
Other Criteria	Hyperkalemic Periodic Paralysis (HyperPP) and Related Variants: Patient has a confirmed diagnosis of primary hyperkalemic periodic paralysis by meeting at least ONE of the following criteria: Patient has had an increase from baseline in serum potassium concentration of greater than or equal to 1.5 mEq/L during a paralytic attack OR Patient has had a serum potassium concentration during a paralytic attack of greater than 5.0 mEq/L OR Patient has a family history of the condition OR Patient has a genetically confirmed skeletal muscle sodium channel mutation AND The prescribing physician has excluded other reasons for acquired hyperkalemia (e.g., drug abuse, renal and adrenal dysfunction) For Continuation of treatment a patient has decrease in the frequency or severity of paralytic attacks with treatment as determined by the prescribing physician. For Hypokalemic Periodic Paralysis (HypoPP) and Related Variants for Initiation of treatment: Patient has a confirmed diagnosis of primary hypokalemic periodic paralysis by meeting at least ONE of the following: Patient has had a serum potassium concentration of less than 3.5 mEq/L during a paralytic attack OR Patient has a family history of the condition OR Patient has a genetically confirmed skeletal muscle calcium or sodium channel

ConnectiCare

PA Criteria	Criteria Details
	mutation AND Patient has had improvements in paralysis attack symptoms with potassium intake. For Continuation of treatment: Patient has decrease in the frequency or severity of paralytic attacks with treatment as determined by the prescribing physician

ConnectiCare

KISQALI

Products Affected

- Kisqali Femara Co-Pack oral tablet 200 mg/day(200 mg x 1)-2.5 mg, 400 mg/day(200 mg x 2)-2.5 mg, 600 mg/day(200 mg x 3)-2.5 mg
- Kisqali oral tablet 200 mg/day (200 mg x 1), 400 mg/day (200 mg x 2), 600 mg/day (200 mg x 3)

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Use as monotherapy, pregnancy
Required Medical Information	Hormone receptor (HR) status, human epidermal growth factor receptor 2 (HER2) status, menopause status, previous therapies tried
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an oncologist
Coverage Duration	12 months
Other Criteria	For pre/perimenopausal or postmenopausal women, patient has hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer and Kisqali is being used in combination with an aromatase inhibitor as initial endocrine-based therapy. For postmenopausal women with HR-positive, HER-2 negative advanced or metastatic breast cancer, Kisqali (single agent) is being used in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy.

ConnectiCare

KORLYM

Products Affected

- Korlym

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Pregnancy. Patients taking simvastatin, lovastatin, and CYP3A substrates with narrow therapeutic ranges, such as cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus. Concomitant treatment with systemic corticosteroids for serious medical conditions or illnesses. Women with a history of unexplained vaginal bleeding. Women with endometrial hyperplasia with atypia or endometrial carcinoma.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

KUVAN

Products Affected

- Kuvan oral tablet,soluble

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Blood phenylalanine (Phe) levels. Pretreatment blood phenylalanine (Phe) levels greater than 10mg/dL if the patient is older than 12 years of age or greater than 6mg/dL if less than or equal to 12 years of age. Response to a therapeutic trial (greater than or equal to a 30% reduction in blood Phe levels) is required for long-term authorization.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	2 months initial, 12 months on renewal
Other Criteria	Blood Phe levels should be checked after 1 week of therapy and periodically up to one month during a therapeutic trial.

ConnectiCare

KYNAMRO

Products Affected

- Kynamro

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Current LDL-C (within the past 30 days), prior therapies tried
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For HoFH approve after trial of Repatha.

ConnectiCare

LENVIMA

Products Affected

- Lenvima oral capsule 10 mg/day (10 mg x 1), 14 mg/day(10 mg x 1-4 mg x 1), 18 mg/day (10 mg x 1-4 mg x2), 20 mg/day (10 mg x 2), 24 mg/day(10 mg x 2-4 mg x 1), 8 mg/day (4 mg x 2)

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	Differentiated Thyroid Cancer - must be locally recurrent or metastatic, progressive refractory to radioactive iodine treatment for approval. Advanced Renal Cell Carcinoma - must be used in combination with everolimus following one prior anti-angiogenic therapy (eg, Inlyta, Votrient, Sutent, Nexavar).

ConnectiCare

LETAIRIS

Products Affected

- Letairis

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Pregnancy, idiopathic pulmonary fibrosis, including idiopathic pulmonary fibrosis patients with pulmonary hypertension (WHO group 3).
Required Medical Information	PAH WHO group, right heart catheterization
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or pulmonologist
Coverage Duration	12 months
Other Criteria	Pulmonary arterial hypertension (PAH) WHO Group 1 patients not currently on Letairis or another agent indicated for WHO Group 1 PAH are required to have had a right-heart catheterization to confirm the diagnosis of PAH to ensure appropriate medical assessment. PAH WHO Group 1 patients currently on Letairis or another agent indicated for WHO Group 1 PAH may continue therapy without confirmation of a right-heart catheterization.

ConnectiCare

LEUKINE

Products Affected

- Leukine injection recon soln

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Administration within 24 hours preceding or following chemotherapy or radiotherapy, hypersensitivity to yeast-derived products. For prophylaxis of febrile neutropenia: use to increase the chemotherapy dose intensity or dose schedule above established regimens. For treatment of febrile neutropenia, when patient receives Neulasta during the current chemotherapy cycle. For AML only, excessive (greater than or equal to 10%) leukemic myeloid blasts in the bone marrow or peripheral blood.
Required Medical Information	For patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy: Leukine may be used for the prevention of chemotherapy-induced febrile neutropenia if the patient experienced febrile neutropenia with a prior chemotherapy cycle OR the patient is at risk of developing febrile neutropenia. Leukine is allowable for the treatment of febrile neutropenia in patients who have received prophylaxis with Leukine (or Neupogen) OR in patients at risk for infection-related complications.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A

ConnectiCare

LEUPROLIDE

Products Affected

- Eligard
- Eligard (3 month)
- Eligard (4 month)
- Eligard (6 month)
- leuprolide subcutaneous kit
- Lupron Depot
- Lupron Depot (3 month)
- Lupron Depot (4 month)
- Lupron Depot (6 Month)

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D but specific to the following drugs as follows: Prostate cancer (Lupron Depot [7.5 mg-1mo, 22.5 mg-3-mo, 30 mg-4-mo, 45 mg-6-mo] OR Eligard [7.5 mg-1-mo, 22.5mg-3-mo, 30 mg-4-mo, 45 mg-6-mo]), Endometriosis (Lupron Depot [3.75 mg-1-mo, 11.25 mg-3-mo]), Uterine leiomyomata (Lupron Depot [3.75 mg-1-mo, 11.25 mg-3-mo]), Treatment of central precocious puberty (Lupron Depot Ped [11.25 mg-1-mo, 15 mg-1-mo]). Ovarian cancer (Lupron Depot [7.5 mg-1-mo]). Breast cancer (Lupron Depot [3.75 mg-1-mo, 11.25 mg-3-mo]). Prophylaxis or treatment of uterine bleeding in premenopausal women with hematologic malignancy or prior to bone marrow/stem cell transplantation (BMT/SCT) (Lupron Depot [3.75 mg-1-mo, 7.5 mg-1-mo]).
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	For abnrml uterine bleeding, uterine leiomyomata,endometriosis-6 mo.All other=12 months
Other Criteria	N/A

ConnectiCare

LIDOCAINE PATCH

Products Affected

- lidocaine topical adhesive patch,medicated

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus diabetic neuropathic pain.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For diabetic neuropathic pain: the patient must have previous use and inadequate response or intolerance to any ONE medication that is FDA-labeled for diabetic peripheral neuropathy, including (but not limited to) duloxetine and Lyrica.

ConnectiCare

LINEZOLID

Products Affected

- linezolid
- linezolid in dextrose 5%

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Culture and sensitivity and CBC within normal limits
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	28 days
Other Criteria	N/A

ConnectiCare

LONG ACTING OPIOIDS

Products Affected

- KADIAN ORAL CAPSULE, EXTENDED RELEASE PELLETS 200 MG
- methadone oral solution 10 mg/5 mL, 5 mg/5 mL
- methadone oral tablet 10 mg, 5 mg
- morphine oral capsule, ER multiphase 24 hr 120 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg
- morphine oral capsule,extend.release pellets 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg
- morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg
- oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D worded as pain severe enough to require daily, around-the-clock, long-term opioid treatment. Plus patients with a cancer diagnosis, patients in a hospice program/end-of-life care/palliative care.
Exclusion Criteria	Acute (ie, non-chronic) pain
Required Medical Information	Pain type (chronic vs acute), prior pain medications/therapies tried, concurrent pain medications/therapies
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	For pain severe enough to require daily, around-the-clock, long-term opioid treatment (with no cancer diagnosis and not in hospice), approve if all of the following criteria are met: 1) patient is not opioid naive, AND 2) non-opioid therapies have been optimized and are being used in conjunction with opioid therapy according to the prescribing physician, AND 3) the prescribing physician has checked the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP), unless unavailable in the state, AND 4) the prescribing physician has discussed risks (eg, addiction, overdose) and realistic benefits of opioid

PA Criteria	Criteria Details
	therapy with the patient, AND 5) according to the prescriber physician there is a treatment plan (including goals for pain and function) in place and reassessments are scheduled at regular intervals. Clinical criteria incorporated into the quantity limit edits for all oral long-acting opioids require confirmation that the indication is intractable pain (ie, FDA labeled use) prior to reviewing for quantity exception.

ConnectiCare

LONSURF

Products Affected

- Lonsurf

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Treatment-naive patients
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For Metastatic colorectal cancer, patient must have previously been treated with a fluoropyrimidine (e.g., capecitabine, 5-FU)-, AND oxaliplatin-, AND irinotecan based chemotherapy AND an anti-VEGF therapy AND if RAS wild-type, an anti-EGFR therapy.

ConnectiCare

LYNPARZA

Products Affected
- Lynparza

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies, A deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer as detected by an FDA-approved test.
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	A documented diagnosis of advanced ovarian cancer which has been treated with at least three prior lines of chemotherapy. Maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, in patients who are in a complete or partial response to platinum-based chemotherapy.

ConnectiCare

MEGESTROL

Products Affected

- megestrol oral suspension 400 mg/10 mL (40 mg/mL), 625 mg/5 mL

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

MEKINIST

Products Affected

- Mekinist

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	For a diagnosis of melanoma, patients who have progressed on prior BRAF-inhibitor therapy
Required Medical Information	Documentation of the detected BRAFV600E or BRAFV600K mutation
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For Unresectable or metastatic, malignant melanoma, with BRAF V600E or V600K mutation, Mekinist will be used as monotherapy or in combination with Tafinlar. For the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, must be used in combination with Tafinlar following complete resection (with lymph node involvement). For metastatic NSCLC with BRAF V600E mutation, must be used in combination with Tafinlar. For locally advanced or metastatic anaplastic thyroid carcinoma with BRAF V600E mutation and no satisfactory locoregional treatment options, must be used in combination with Tafinlar.

ConnectiCare

MEMANTINE

Products Affected

- memantine oral capsule,sprinkle,ER 24hr
- memantine oral solution
- memantine oral tablet
- memantine oral tablets,dose pack

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

METHAMPHETAMINE

Products Affected

- methamphetamine

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

MODAFINIL

Products Affected

- modafinil

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients must be greater than or equal to 17 years of age.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Excessive sleepiness due to SWSD if the patient is working at least 5 overnight shifts per month.

ConnectiCare

NATPARA

Products Affected

- Natpara

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Hypoparathyroidism caused by calcium-sensing receptor mutations. Patients with acute post-surgical hypoparathyroidism.
Required Medical Information	Serum calcium level
Age Restrictions	18 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

NERLYNX

Products Affected

- Nerlynx

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Trastuzumab treatment naive patients, HER2-negative patients, ALT greater than 5-20 times the upper limit of normal, bilirubin greater than 3-10 times the upper limit of normal, concomitant use with proton pump inhibitors.
Required Medical Information	Diagnosis, human epidermal growth factor receptor 2 (HER2) status, previous therapies tried, patient has early stage breast cancer
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with, an oncologist
Coverage Duration	12 months
Other Criteria	Nerlynx is being used for extended adjuvant treatment of early stage breast cancer with HER2 overexpression and patient has received adjuvant treatment with trastuzumab based therapy

ConnectiCare

NEUPOGEN

Products Affected
- Neupogen

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Administration within 24 hours preceding or following chemotherapy or radiotherapy, E coli hypersensitivity. For prophylaxis of febrile neutropenia: use to increase the chemotherapy dose intensity or dose schedule beyond established regimen. For treatment of febrile neutropenia, when patient receives Neulasta during the current chemotherapy cycle.
Required Medical Information	For patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy: Neupogen may be used for the prevention of chemotherapy-induced febrile neutropenia if the patient experienced febrile neutropenia with a prior chemotherapy cycle OR the patient is at risk of developing febrile neutropenia. Neupogen is allowable for the treatment of febrile neutropenia in patients who have received prophylaxis with Neupogen (or Leukine) OR in patients at risk for infection-related complications.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A

ConnectiCare

NEUPRO

Products Affected

- Neupro

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

NEXAVAR

Products Affected

- Nexavar

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapy
Age Restrictions	18 years of age or older
Prescriber Restrictions	Oncologist
Coverage Duration	12 months
Other Criteria	For locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC), patient must have history of refractory radioactive iodine treatment.

ConnectiCare

NINLARO

Products Affected

- Ninlaro

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Previous therapies tried and failed, baseline CBC
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For multiple myeloma, patient has received at least one prior therapy AND will be used in combination with lenalidomide and dexamethasone.

ConnectiCare

NORTHERA

Products Affected

- Northera

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Documentation from the medical record of diagnosis and prior medication history
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or a neurologist
Coverage Duration	Initial 4 weeks, renewal 6 months
Other Criteria	NOH, approve if the patient meets ALL of the following criteria: a) Patient has been diagnosed with symptomatic NOH due to primary autonomic failure (Parkinsons disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy, AND b) Patient has tried midodrine

ConnectiCare

NUEDEXTA

Products Affected

- Nuedexta

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with, a neurologist.
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

NUPLAZID

Products Affected

- Nuplazid oral tablet 17 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

OCTREOTIDE

Products Affected

- octreotide acetate injection solution

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

ODOMZO

Products Affected

- Odomzo

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For locally advanced basal cell carcinoma (BCC) has recurred following surgery or radiation therapy or if the patient is not a candidate for surgery and the patient is not a candidate for radiation therapy, according to the prescribing physician.

ConnectiCare

OFEV

Products Affected

- Ofev

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Combination use with pirfenidone
Required Medical Information	N/A
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in combination with a pulmonologist
Coverage Duration	12 months
Other Criteria	IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP.

ConnectiCare

ONFI

Products Affected

- Onfi oral suspension
- Onfi oral tablet 10 mg, 20 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	The patient will receive Onfi for the treatment of seizures associated with Lennox-Gastaut syndrome.
Age Restrictions	2 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

OPSUMIT

Products Affected

- Opsumit

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Pregnancy
Required Medical Information	PAH WHO group, right heart catheterization
Age Restrictions	N/A
Prescriber Restrictions	PAH - must be prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	12 months
Other Criteria	Pulmonary arterial hypertension (PAH) WHO Group 1 patients not currently on Opsumit or another agent indicated for WHO Group 1 PAH are required to have had a right-heart catheterization to confirm the diagnosis of PAH to ensure appropriate medical assessment. PAH WHO Group 1 patients currently on Opsumit or another agent indicated for WHO Group 1 PAH may continue therapy without confirmation of a right-heart catheterization.

ConnectiCare

ORENCIA

Products Affected

- Orencia ClickJect
- Orencia subcutaneous syringe 125 mg/mL, 50 mg/0.4 mL, 87.5 mg/0.7 mL

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
Required Medical Information	Diagnosis, concurrent medications, previous therapies tried.
Age Restrictions	Juvenile idiopathic arthritis (JIA)- 2 years or older. Psoriatic arthritis (PsA), Rheumatoid arthritis (RA)- 18 years and older. Orencia ClickJect autoinjector- 18 years and older.
Prescriber Restrictions	For RA and JIA, must be prescribed by, or in consultation with, a rheumatologist. For PsA, must be prescribed by, or in consultation with, a rheumatologist or dermatologist.
Coverage Duration	12 months
Other Criteria	For RA, patient has tried one conventional synthetic DMARD for at least 3 months. Patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD. For JIA, approve if the patient has aggressive disease or the patient has tried one other agent for this condition (eg, MTX, sulfasalazine, leflunomide, NSAID, biologic DMARD).

ConnectiCare

ORKAMBI

Products Affected

- Orkambi oral tablet

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Combination use with Kalydeco
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	CF - homozygous for the Phe508del (F508del) mutation in the CFTR gene (meaning the patient has two copies of the Phe508del mutation)

ConnectiCare

OTEZLA

Products Affected

- Otezla
- Otezla Starter oral tablets,dose pack 10 mg (4)-20 mg (4)-30 mg (47)

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous therapies tried.
Age Restrictions	18 years and older
Prescriber Restrictions	For Psoriatic Arthritis (PsA), must be prescribed by, or in consultation with, a dermatologist or rheumatologist. For Plaque psoriasis (PP), must be prescribed by, or in consultation with, a dermatologist.
Coverage Duration	12 months
Other Criteria	For PP, approve if the patient has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant. Patients who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first.

ConnectiCare

PEGASYS

Products Affected

- Pegasys subcutaneous solution
- Pegasys subcutaneous syringe

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

PENICILLAMINE

Products Affected

- Cuprimine
- Depen Titratabs

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

PHENOXYBENZAMINE

Products Affected

- phenoxybenzamine

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

PLEGRIDY

Products Affected

- Plegridy subcutaneous pen injector 125 mcg/0.5 mL, 63 mcg/0.5 mL- 94 mcg/0.5 mL
- Plegridy subcutaneous syringe 125 mcg/0.5 mL, 63 mcg/0.5 mL- 94 mcg/0.5 mL

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use of other disease-modifying agents used for multiple sclerosis (MS)
Required Medical Information	Multiple Sclerosis (MS) diagnosis worded or described as patients with a diagnosis of MS or have experienced an attack and who are at risk of MS.
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, a neurologist or physician who specializes in the treatment of MS.
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

POMALYST

Products Affected

- Pomalyst

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis, prior therapies, for female patients of childbearing potential, pregnancy is excluded by 2 negative serum or urine pregnancy tests. For all patients, complete blood counts are monitored for hematologic toxicity while receiving Pomalyst.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist or Hematologist
Coverage Duration	12 months
Other Criteria	For multiple myeloma must be used in combination with dexamethasone and patient has received at least two prior therapies including lenalidomide and a proteasome inhibitor and has demonstrated disease progression on or within 60 days of completion of the last therapy. Male and female patients of child-bearing potential should be instructed on the importance of proper utilization of appropriate contraceptive methods for Pomalyst use. Patients should be monitored for signs and symptoms of thromboembolism.

ConnectiCare

PRALUENT

Products Affected

- Praluent Pen subcutaneous pen injector
  150 mg/mL, 75 mg/mL

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use of Praluent with Repatha, Juxtapid or Kynamro.
Required Medical Information	Current LDL-C (within the past 90 days), prior therapies tried, medication adverse event history
Age Restrictions	18 years of age and older.
Prescriber Restrictions	Prescribed by, or in consultation with, a cardiologist, endocrinologist, or a physician who focuses in the treatment of CV risk management and/or lipid disorders
Coverage Duration	12 months
Other Criteria	Hyperlipidemia in pts w/ (ASCVD) apprv if the pt has a curr LDL-C lvl of grtr or eq to 70 mg/dL w/in the past 90 ds (after tx with antihyperlipidemic agnts but prior to PCSK9 inh tx such as Praluent or Repatha) AND the pt has had one of the following conds or dxs: prev MI,OR has a hx of an acute coronary syndrome, OR The pt has a dx of angina (stable or unstable) ,OR The pt has a past hx of stroke or TIA, OR The pt has PAD, The pt has undergone a coronary or other arterial revascularization procedure AND The pt has tried 1 high-intensity statin tx (i.e., atorvastatin 80 mg daily or Crestor 40 mg daily) for equal or more than 12 cont wks AND the LDL-C lvl remains equal or more than70 mg/dL unless pt experienced statin-related rhabdomyolysis, OR the pt experienced skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the skeletal-related symptoms resolved during d/c. AND If pt able to tolerate statins cont to rec. the max tolerated dose of a statin while rec. Praluent tx. Heterozygous Familial Hypercholesterolemia apprve if the pt has a curnt LDL-C lvl eq or more than 100 mg/dL w/in the past 30 days, AND the pts dx of HeFH is def as probable or definite by WHO/Dutch Lipid grp criteria OR definite by Simon-Broome Criteria OR

PA Criteria	Criteria Details
	genetic testing, AND The pt has tried 1 high-intensity statin txs (i.e., atorvastatin 80 mg daily or Crestor 40 mg daily) for equal or more than 12 cont wks, AND the LDL-C lvl remains eq or more than 100 mg/dL, unless pt experienced statin-related rhabdomyolysis, OR the pt experienced skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the skeletal-related symptoms resolved during d/c. AND If pt able to tolerate statins cont to rec. the max tolerated dose of a statin while rec. Praluent tx.

ConnectiCare

PREVYMIS

Products Affected

- Prevymis oral

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Concurrent use with pimozide, ergot alkaloids (e.g. ergotamine, dihydroergotamine), concurrent use with either pitavastatin or simvastatin when letermovir is being used in combination with cyclosporine, initiation of therapy after day 28 following transplant, treatment beyond day 100 following transplant
Required Medical Information	Diagnosis, patient has received allogeneic hematopoietic stem cell transplant (HSCT), the HSCT procedure date, confirmation that patient is CMV-seropositive
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with, a physician who specializes in infectious disease, hematology, oncology or transplant specialist.
Coverage Duration	100 days
Other Criteria	For the prophylaxis of CMV infection and disease, patient is CMV seropositive, patient has received an HSCT, and therapy is being initiated between day 0 and day 28 following transplant.

ConnectiCare

PROCRIT

Products Affected

- Procrit injection solution 10,000 unit/mL, 2,000 unit/mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL, 40,000 unit/mL

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D worded as anemia associated with chronic renal failure (CRF), including patients on dialysis and not on dialysis, and worded as anemia secondary to myelosuppressive anticancer chemotherapy in solid tumors, multiple myeloma, lymphoma, and lymphocytic leukemia, . Plus anemia in patients with HIV who are receiving zidovudine. Anemic patients (Hb of 13.0 g/dL or less) at high risk for perioperative transfusions (secondary to significant, anticipated blood loss and are scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions). Additional off-label coverage is provided for Anemia due to myelodysplastic syndrome (MDS), Anemia associated with use of ribavirin therapy for hepatitis C, and Anemia in HIV-infected patients.
Exclusion Criteria	N/A
Required Medical Information	CRF anemia in patients on and not on dialysis. Hemoglobin (Hb) of less than 10.0 g/dL to start. Hb less than or equal to 10 g/dL for adults (CKD, not on dialysis), 11 g/dL (CKD on dialysis) or 12 g/dL or less for pediatric CKD. Anemia w/myelosuppressive chemotx.pt must be currently receiving myelosuppressive chemo and Hb less than or equal to 10.0 g/dL. MDS, approve if Hb is 10 g/dL or less. Surgical pts to reduce RBC transfusions - pt is unwilling or unable to donate autologous blood prior to surgery
Age Restrictions	MDS anemia/HepC anemia = 18 years of age and older
Prescriber Restrictions	MDS anemia, prescribed by or in consultation with, a hematologist or oncologist. Hep C anemia, prescribed by or in consultation with hepatologist, gastroenterologist, hematologist or infectious disease physician who specializes in the management of hepatitis C.
Coverage Duration	Anemia w/myelosuppress = 4 mos.Transfus=1 mo.Other= 6mo. HIV + zidovudine = 4 mo
Other Criteria	Part B versus Part D determination will be made at time of prior

PA Criteria	Criteria Details
	authorization review per CMS guidance to establish if the drug prescribed is to be used for an end-stage renal disease (ESRD)-related condition.

ConnectiCare

PROLIA

Products Affected

- Prolia

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concomitant use with other medications for osteoporosis (eg, denosumab [Prolia], bisphosphonates, raloxifene, calcitonin nasal spray [Miacalcin, Fortical]), except calcium and Vitamin D.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Treatment of postmenopausal osteoporosis/Treatment of osteoporosis in men (to increase bone mass), approve if the patient meets one of the following: 1. has had inadequate response after 12 months of therapy with an oral bisphosphonate, had osteoporotic fracture while receiving an oral bisphosphonate, or intolerability to an oral bisphospohate, OR 2. the patient cannot take an oral bisphosphonate because they cannot swallow or have difficulty swallowing, they cannot remain in an upright position, or they have a pre-existing GI medical condition, OR 3. pt has tried an IV bisphosphonate (ibandronate or zoledronic acid), OR 4. the patient has severe renal impairment (eg, creatinine clearance less than 35 mL/min) or chronic kidney disease, or if the patient has multiple osteoporotic fractures. Treatment of bone loss in men at high risk for fracture receiving ADT for nonmetastatic prostate cancer, approve if the patient has prostate cancer that is not metastatic to the bone and the patient is receiving ADT (eg, leuprolide, triptorelin, goserelin) or the patient has undergone a bilateral orchiectomy. Treatment of bone loss (to increase bone mass) in patients at high risk for fracture receiving adjuvant AI therapy for breast cancer, approve if the patient has breast cancer that is not metastatic to the bone

ConnectiCare

PA Criteria	Criteria Details
	and is receiving concurrent AI therapy (eg, anastrozole, letrozole, exemestane). Treatment of glucocorticoid induced osteoporosis (GIO), approve if: pt is initiating or continuing therapy with systemic glucocorticoids, AND has had an inadequate response after a trial duration of 12 months (eg, ongoing and significant loss of BMD, lack of BMD increase) or patient had an osteoporotic fracture while receiving therapy or patient experienced intolerability (eg, severe GI-related adverse effects, severe musculoskeletal-related side effects, a femoral fracture), OR pt cannot take an oral bisphosphonate because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphosphonate administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]).

ConnectiCare

PROMACTA

Products Affected

- Promacta

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Thrombocytopenia due to hepatitis C virus (HCV)-related cirrhosis.
Exclusion Criteria	Use in the management of thrombocytopenia in myelodysplastic syndrome (MDS). Use in combination with Nplate for treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia purpura.
Required Medical Information	Cause of thrombocytopenia.
Age Restrictions	N/A
Prescriber Restrictions	Treatment of thrombocytopenia due to chronic immune (idiopathic) thrombocytopenic purpura (ITP), approve if prescribed by, or after consultation with, a hematologist. Treatment of thrombocytopenia due to HCV-related cirrhosis, approve if prescribed by, or after consultation with, either a hematologist, gastroenterologist, a hepatologist, or a physician who specializes in infectious disease.
Coverage Duration	12 months
Other Criteria	Thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia purpura, approve if the patient has tried corticosteroids or IVIG or has undergone a splenectomy. Treatment of thrombocytopenia due to HCV-related cirrhosis, approve to allow for initiation of antiviral therapy if the patient has low platelet counts (eg, less than 75,000 mm3) and the patient has chronic HCV infection and is a candidate for hepatitis C therapy .

ConnectiCare

QUININE

Products Affected

- quinine sulfate

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

RAVICTI

Products Affected

- Ravicti

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

REBIF

Products Affected

- Rebif (with albumin)
- Rebif Rebidose subcutaneous pen injector 22 mcg/0.5 mL, 44 mcg/0.5 mL, 8.8mcg/0.2mL-22 mcg/0.5mL (6)
- Rebif Titration Pack

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

REPATHA

Products Affected

- Repatha
- Repatha Pushtronex
- Repatha SureClick

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use of Repatha with Praluent, Juxtapid or Kynamro
Required Medical Information	Current LDL-C (within the past 90 days), prior therapies tried, medication adverse event history
Age Restrictions	ASCVD/HeFH/Primary Hyperlipidemia - 18 yo and older, HoFH 13 yo and older.
Prescriber Restrictions	Prescribed by, or in consultation with, a cardiologist, endocrinologist, or a physician who focuses in the treatment of CV risk management and/or lipid disorders
Coverage Duration	12 months
Other Criteria	Hyperlipidemia in pts w/ (ASCVD) apprv if the pt has a curr LDL-C lvl of grtr or eq to 70 mg/dL w/in the past 90 ds (after tx with antihyperlipidemic agnts but prior to PCSK9 inh tx such as Praluent or Repatha) AND the pt has had one of the following conds or dxs: prev MI,OR has a hx of an acute coronary syndrome, OR The pt has a dx of angina (stable or unstable) ,OR The pt has a past hx of stroke or TIA, OR The pt has PAD, The pt has undergone a coronary or other arterial revascularization procedure AND The pt has tried 1 high-intensity statin tx (i.e., atorvastatin 80 mg daily or Crestor 40 mg daily) for equal or more than 12 cont wks AND the LDL-C lvl remains equal or more than70 mg/dL unless pt experienced statin-related rhabdomyolysis, OR the pt experienced skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the skeletal-related symptoms resolved during d/c. AND If pt able to tolerate statins cont to rec. the max tolerated dose of a statin while rec. Repatha tx. Heterozygous Familial Hypercholesterolemia apprve if the pt has a curnt LDL-C lvl eq or more than 100 mg/dL w/in the past 30 days, AND the pts dx of HeFH is def as probable or definite by

ConnectiCare

PA Criteria	Criteria Details
	WHO/Dutch Lipid grp criteria OR definite by Simon-Broome Criteria OR genetic testing, AND The pt has tried 1 high-intensity statin txs (i.e., atorvastatin 80 mg daily or Crestor 40 mg daily) for equal or more than 12 cont wks, AND the LDL-C lvl remains eq or more than 100 mg/dL, unless pt experienced statin-related rhabdomyolysis, OR the pt experienced skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the skeletal-related symptoms resolved during d/c. AND If pt able to tolerate statins cont to rec. the max tolerated dose of a statin while rec. Repatha tx. Primary hyperlipidemia apprve if the pt has a curnt LDL-C lvl eq or more than 100 mg/dL w/in the past 90 days, AND The pt has tried 1 high-intensity statin txs (i.e., atorvastatin 80 mg daily or Crestor 40 mg daily) for equal or more than 12 cont wks, AND the LDL-C lvl remains eq or more than 100 mg/dL, unless pt experienced statin-related rhabdomyolysis, OR the pt experienced skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the skeletal-related symptoms resolved during d/c. AND If pt able to tolerate statins cont to rec. the max tolerated dose of a statin while rec. Repatha tx.

ConnectiCare

REVATIO

Products Affected

- sildenafil (Pulmonary Arterial Hypertension) oral

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Nitrate therapy
Required Medical Information	Diagnosis of pulmonary arterial hypertension (PAH), (WHO Group 1). PAH been confirmed by right heart catheterization.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

REVLIMID

Products Affected

- Revlimid

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Pregnancy
Required Medical Information	For active myeloma patient meets one of the following: 1) Revlimid is used in combination with dexamethasone. 2) Revlimid is used as maintenance monotherapy following response to either stem cell transplant or primary induction therapy. For mantle cell lymphoma (MCL): Revlimid is used after 2 prior therapies, 1 of which is bortezomib. For Low or Intermediate-1 Risk myelodysplastic syndrome (MDS): for those with 5q deletion, patients should have transfusion-dependent anemia or symptomatic anemia with clinically significant cytopenias. For those with non-5q deletion MDS and symptomatic anemia, patients should have failed to respond to epoetin alfa or darbepoetin or have a pretreatment serum erythropoietin levels greater than 500 mU/mL and a low probability of response to immunosuppressive therapy. For female patients of childbearing potential, pregnancy is excluded by 2 negative serum or urine pregnancy tests. For all patients, complete blood counts are monitored for hematologic toxicity while receiving Revlimid.
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	Male and female patients of child-bearing potential should be instructed on the importance of proper utilization of appropriate contraceptive methods for Revlimid use. Patients should be monitored for signs and symptoms of thromboembolism.

ConnectiCare

RIBAVIRIN

Products Affected

- ribavirin oral capsule
- ribavirin oral tablet 200 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Hemoglobinopathy. History of pre-existing heart disease. Creatinine clearance less than 50 mL/minute and unwilling to use modified dose of ribavirin. Pregnancy (self or partner).Unwilling to use effective contraception. Coadministration with didanosine in HIV coinfected patients.
Required Medical Information	Prior to initiating therapy, detectable levels of HCV RNA in the serum. Must use in combination with Harvoni, interferon, Viekira, Daklinza, Technivie, Zepatier or Sovaldi. Cirrhosis documented by FibroScan, liver biopsy, or radiological imaging. genotype
Age Restrictions	N/A
Prescriber Restrictions	ID specialist, gastroenterologist, or oncologist
Coverage Duration	12 wks, 24 wks, or 48 wks as specified in Other Criteria.
Other Criteria	Criteria will be applied consistent with current AASLD-IDSA guidance

ConnectiCare

RUBRACA

Products Affected

- Rubraca

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, Prior therapies, documentation of the presence of a deleterious BRCA mutation (germline and/or somatic)
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by or in consultation with Oncologist
Coverage Duration	12 months
Other Criteria	Patient selection must be based on an FDA-approved companion diagnostic. Patient must have been treated with two or more chemotherapies prior to Rubraca. Rubraca must be used as monotherapy.

ConnectiCare

RYDAPT

Products Affected

- Rydapt

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	For AML, use as monotherapy for the treatment of patients with AML and patients with FLT3-mutation negative disease, Pediatric patients
Required Medical Information	Diagnosis, for AML, patients must have the FLT3-mutation, as detected by an FDA approved test
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	For AML - 6 months, for Systemic Mast Cell Disease - 12 months
Other Criteria	For AML, patient is newly diagnosed, AND Rydapt will be used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation therapy AND the patient has FLT3-mutation positive AML as detected by an FDA approved test AND patient is receiving Rydapt on days 8-21 of each cycle of induction with cytarabine and daunorubicin and on days 8-21 of each cycle of consolidation with high-dose cytarabine

ConnectiCare

SAMSCA

Products Affected

- Samsca oral tablet 15 mg, 30 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Up to 30 days
Other Criteria	N/A

ConnectiCare

SIGNIFOR

Products Affected

- Signifor

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which Signifor is being used.
Age Restrictions	Cushing's, 18 years of age and older.
Prescriber Restrictions	Initial course, prescribed by or in consultation with an endocrinologist.
Coverage Duration	Initial therapy, approve for 3 months. Continuation therapy, approve for 12 months
Other Criteria	Cushing's disease, approve if according to the prescribing physician the patient is not a candidate for surgery or surgery has not been curative. Patients who have already been started on Signifor for Cushing's disease will be approved if the patient has had a response, as determined by the prescribing physician and the patient is continuing therapy to maintain response.

ConnectiCare

SPRYCEL

Products Affected

- Sprycel oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Acute lymphoblastic leukemia (ALL) and newly diagnosed chronic myeloid leukemia (CML) must be positive for the Philadelphia chromosome or BCR-ABL gene. For CML, patient meets one of the following: 1) newly diagnosed in chronic phase, 2) resistance or intolerance to imatinib, or 3) relapse after stem cell transplant. For ALL, resistance or intolerance to prior therapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

STELARA

Products Affected

- Stelara subcutaneous

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
Required Medical Information	Diagnosis, concurrent medications, previous therapies tried.
Age Restrictions	Plaque psoriasis (PP)- 12 years and older. Crohn's disease (CD) and Psoriatic arthritis (PsA)- 18 years and older.
Prescriber Restrictions	For PP, must be prescribed by, or in consultation with, a dermatologist. For PsA, must be prescribed by, or in consultation with, a rheumatologist or dermatologist. For CD, must be prescribed by, or in consultation with, a gastroenterologist.
Coverage Duration	12 months
Other Criteria	For PP, approve if the patient has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant. Patients who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first. For CD, approve if the patient meets the following criteria: patient has tried corticosteroids or patient has tried one other agent for CD AND patient has received a single IV loading dose. Clinical criteria incorporated into the Stelara 90 mg quantity limit edit, approve additional quantity (to allow for 90 mg every 8 weeks) if the patient has a diagnosis of CD.

ConnectiCare

STIVARGA

Products Affected

- Stivarga

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Stivarga for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which Stivarga is being used. For metastatic colorectal cancer (CRC)and gastrointestinal stromal tumors (GIST), prior therapies tried. For metastatic CRC, KRAS mutation status.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For metastatic CRC with KRAS mutation, patient must have been treated with ALL of the following for approval: a fluoropyrimidine (eg, Xeloda, 5-FU), oxaliplatin, irinotecan, anti-VEGF therapy (eg, Avastin, Zaltrap). For metastatic CRC with no detected KRAS mutation (KRAS wild-type), patient must ALSO have been treated with an anti-EGFR therapy (eg, Eribitux, Vectibix). For GIST, patient must have previously been treated with imatinib and sunitinib (Sutent). For Liver carcinoma, patient must have been previously treated with sorafenib (Nexavar).

ConnectiCare

SUTENT

Products Affected

- Sutent

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Clinical manifestations of congestive heart failure.
Required Medical Information	Diagnosis, prior therapies, For gastrointestinal stromal tumor (GIST), disease progression while on an at least 30-day regimen of imatinib or intolerance to imatinib is required.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	Therapy will be interrupted for serious hepatic adverse events and discontinued if serious hepatic adverse events do not resolve.

ConnectiCare

SYLATRON

Products Affected

- Sylatron

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

SYMDEKO

Products Affected

- Symdeko

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Combination therapy with Orkambi or Kalydeco.
Required Medical Information	Diagnosis, Cystic Fibrosis Transmembrane Regulator (CFTR) gene mutation, Current medication regimen
Age Restrictions	12 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with, a pulmonologist or a physician who specializes in the treatment of cystic fibrosis (CF).
Coverage Duration	12 months
Other Criteria	For Cystic Fibrosis, patient must have at least one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, 711+3A G, S945L, S977F, F1052V, E831X, K1060T, A1067T, R1070W, F1074L, D1152H, D1270N, 2789+5G A, 3272-26A G, or 3849 + 10kbC T OR the patient has two copies of the F508del mutation.

ConnectiCare

SYPRINE

Products Affected

- Syprine
- trientine

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous drugs tried.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For Wilson's disease, patient must have history of intolerance, failure or contraindication to penicillamine (i.e., Cuprimine or Depen).

ConnectiCare

TAFINLAR

Products Affected

- Tafinlar

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, Documentation of the detected BRAF V600E or V600K mutations
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For unresectable or metastatic melanoma with BRAF V600K mutation, must be used in combination with Mekinist. For metastatic NSCLC with BRAF V600E mutation, must be used in combination with Mekinist. For locally advanced or metastatic anaplastic thyroid carcinoma with BRAF V600E mutation and no satisfactory locoregional treatment options, must be used in combination with Mekinist.

ConnectiCare

TAGRISSO

Products Affected
- Tagrisso

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus patients already started on Tagrisso for a covered use.
Exclusion Criteria	EGFR tyrosine kinase inhibitor treatment naive patients
Required Medical Information	Confirmed T790M mutation-positive NSCLC as detected by an FDA approved test and Prior therapies tried
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	The patient has metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC as detected by an FDA approved test AND The patient has progressed on or after one of Tarceva (erlotinib tablets), Iressa (gefitinib tablets), or Gilotrif (afatinib tablets) therapy.

ConnectiCare

TARCEVA

Products Affected

- Tarceva oral tablet 100 mg, 150 mg, 25 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	For 1st line therapy of locally advanced or metastatic NSCLC, patient should have a known active EGFR exon 19 deletions or exon 21 substitution mutation or amplification of the EGFR gene.
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For first line treatment of locally advanced, unresectable, or metastatic pancreatic cancer, Tarceva must be used in combination with gemcitabine.

ConnectiCare

TASIGNA

Products Affected

- Tasigna

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Long QT syndrome, uncorrected electrolyte disorders (hypokalemia, hypomagnesemia). Concomitant use with drugs known to prolong the QT interval and strong CYP3A4 inhibitors.
Required Medical Information	Diagnosis, prior therapies tried, Philadelphia chromosome or BCR-ABL gene status, stage of disease (accelerated, chronic).
Age Restrictions	1 year of age and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For adult and pediatric patients with newly diagnosed CML, approve if the patient has Philadelphia chromosome-positive CML in chronic phase. For adult patients with resistant or intolerant CML, approve if the patient has Philadelphia chromosome positive CML in chronic or accelerated phase AND patient has resistance or intolerance to prior therapy that included imatinib. For pediatric patients with resistant or intolerant CML, approve if the patient has Philadelphia chromosome positive CML in chronic phase AND patient has resistance or intolerance to prior tyrosine-kinase inhibitor therapy.

ConnectiCare

TETRABENAZINE

Products Affected

- tetrabenazine

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Tardive dyskinesia (TD). Tourette syndrome and related tic disorders. Hyperkinetic dystonia. Hemiballism.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	For treatment of chorea associated with Huntington's disease, Tourette syndrome or related tic disorders, hyperkinetic dystonia, or hemiballism, must be prescribed by or after consultation with a neurologist. For TD, must be prescribed by or after consultation with a neurologist or psychiatrist.
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

THALOMID

Products Affected

- Thalomid

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Pregnancy
Required Medical Information	For active myeloma, patient meets one of the following: 1) Thalomid is used as salvage or palliative therapy. 2) Thalomid is used for newly diagnosed disease or as primary induction therapy in combination with dexamethasone or in combination with melphalan and prednisone in nontransplant candidates. 3) Thalomid is used as maintenance monotherapy following response to either stem cell transplant or primary induction therapy. For female patients of childbearing potential, pregnancy is excluded by a negative pregnancy test.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Patients are monitored for signs and symptoms of thromboembolism. Male and female patients of child-bearing potential are instructed on the importance of proper utilization of appropriate contraceptive methods.

THIORIDAZINE

Products Affected

- thioridazine

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

TIRF MEDICATIONS

Products Affected

- fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For breakthrough pain in patients with cancer if patient is unable to swallow, has dysphagia, esophagitis, mucositis, or uncontrollable nausea/vomiting OR patient is unable to take 2 other short-acting narcotics (eg, oxycodone, morphine sulfate, hydromorphone, etc) secondary to allergy or severe adverse events AND patient is on or will be on a long-acting narcotic (eg, Duragesic), or the patient is on intravenous, subcutaneous, or spinal (intrathecal, epidural) narcotics (eg, morphine sulfate, hydromorphone, fentanyl citrate). Clinical criteria incorporated into the quantity limit edits for all transmucosal fentanyl drugs require confirmation that the indication is breakthrough cancer pain (ie, FDA labeled use) prior to reviewing for quantity exception.

ConnectiCare

TRACLEER

Products Affected

- Tracleer oral tablet
- Tracleer oral tablet for suspension

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Chronic thromboembolic pulmonary hypertension (CTEPH).
Exclusion Criteria	Pregnancy
Required Medical Information	PAH WHO group, right heart catheterization
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, a cardiologist or a pulmonologist.
Coverage Duration	12 months
Other Criteria	For pulmonary arterial hypertension (PAH) WHO Group 1, patients not currently on Tracleer or another agent indicated for WHO Group 1 PAH are required to have had a right-heart catheterization to confirm the diagnosis of PAH to ensure appropriate medical assessment. PAH WHO Group 1 patients currently on Tracleer or another agent indicated for WHO Group 1 PAH may continue therapy without confirmation of a right-heart catheterization. For CTEPH, patient must have tried Adempas, has a contraindication to Adempas, or is currently receiving Tracleer for CTEPH.

ConnectiCare

TRANSDERMAL FENTANYL

Products Affected

- fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Acute (i.e., non-chronic) pain.
Required Medical Information	Pain type (chronic vs acute), prior pain medications/therapies tried, concurrent pain medications/therapies
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For pain severe enough to require daily, around-the-clock, long-term opioid treatment (with no cancer diagnosis and not in hospice), approve if all of the following criteria are met: 1) patient is not opioid naive, AND 2) non-opioid therapies have been optimized and are being used in conjunction with opioid therapy according to the prescribing physician, AND 3) the prescribing physician has checked the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP), unless unavailable in the state, AND 4) the prescribing physician has discussed risks (eg, addiction, overdose) and realistic benefits of opioid therapy with the patient, AND 5) according to the prescribing physician there is a treatment plan (including goals for pain and function) in place and reassessments are scheduled at regular intervals. Clinical criteria incorporated into the quantity limit edits for all oral long-acting opioids (including transdermal fentanyl products) require confirmation that the indication is intractable pain (ie, FDA labeled use) prior to reviewing for quantity exception.

ConnectiCare

TRETINOIN

Products Affected

- adapalene topical cream
- adapalene topical gel
- tretinoin microspheres topical gel
- tretinoin topical cream
- tretinoin topical gel 0.01 %, 0.025 %

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Coverage is not provided for cosmetic use.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

TYKERB

Products Affected

- Tykerb

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Liver function tests must be monitored at baseline and every four to six weeks during therapy and as clinically indicated. In patients with severe hepatic impairment, Tykerb is used at a reduced dose.
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For advanced or metastatic breast cancer with HER2 overexpression, Tykerb must be used in combination with capecitabine after previous treatment with an anthracycline, a taxane, and trastuzumab. For breast cancer in postmenopausal women with HER2 overexpression, Tykerb must be used in combination with letrozole.

ConnectiCare

UPTRAVI

Products Affected

- Uptravi oral tablet
- Uptravi oral tablets,dose pack

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Breast feeding mother, severe hepatic impairment (Child-Pugh Class C)
Required Medical Information	prior treatments
Age Restrictions	18 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1). Right heart catheterization is NOT required in pts who are currently receiving Uptravi or another agent indicated for PAH (WHO group 1). Patient must have previously tried or is currently taking at least one other agent indicated for PAH treatment (eg, sildenafil, Adcirca, Revatio, Tracleer, Letairis Opsumit, Adempas, Orenitram, Tyvaso, Ventavis, Remodulin, or epoprostenol injection).

ConnectiCare

VENCLEXTA

Products Affected

- Venclexta
- Venclexta Starting Pack

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapy, 17p deletion status
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	CLL - approve if the patient has 17p deletion and has tried one prior therapy.

ConnectiCare

VERZENIO

Products Affected

- Verzenio

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	For monotherapy, patients without prior endocrine therapy and prior chemotherapy, In combination with fulvestrant, patients without prior endocrine therapy.
Required Medical Information	Estrogen receptor (ER) status, Human epidermal growth factor receptor 2 (HER2) status, Previous therapies tried
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an oncologist
Coverage Duration	12 months
Other Criteria	For advanced (metastatic) breast cancer, patient has estrogen receptor-positive (ER+), HER2 negative breast cancer and will be using Verzenio in combination with an aromatase inhibitor as initial endocrine-based therapy and is postmenopausal OR patient had disease progression following endocrine therapy (e.g. anastrozole, letrozole, exemastane, tamoxifen) and will be receiving Verzenio in combination with fulvestrant OR patient had disease progression following endocrine therapy (e.g. anastrozole, letrozole, exemastane, tamoxifen) AND prior chemotherapy and will be receiving Verzenio as monotherapy.

ConnectiCare

VIGABATRIN

Products Affected

- Sabril oral tablet
- vigabatrin

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Patients with or at high risk of vision loss (except patients who have blindness). Patients using other medications associated with serious adverse ophthalmic effects such as retinopathy or glaucoma.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Infantile spasms: initial 4 wks, reauth 6 mths. CPS: initial 3 mths, reauth for 12 months
Other Criteria	N/A

ConnectiCare

VIMPAT

Products Affected

- Vimpat oral solution
- Vimpat oral tablet

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	4 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

ConnectiCare

VOTRIENT

Products Affected

- Votrient

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Alanine transaminase (ALT) greater than 3 times the upper limit of normal (ULN) and bilirubin greater than 2 times the ULN.
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with, an oncologist
Coverage Duration	12 months
Other Criteria	For advanced soft tissue sarcoma, patients must have received prior chemotherapy.

ConnectiCare

XALKORI

Products Affected

- Xalkori

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus, patients with non-small cell lung cancer (NSCLC) already started on crizotinib.
Exclusion Criteria	N/A
Required Medical Information	For the FDA-approved indication of NSCLC for patients new to therapy, ALK status required. ROS1 Status
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	NSCLC, patient must have a tumor that is ALK-positive or ROS1-positive for approval.

ConnectiCare

XATMEP

Products Affected

- Xatmep

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Adult patients. For ALL, use as monotherapy. For pJIA, first-line therapy. Pregnancy.
Required Medical Information	Diagnosis. For pJIA, prior therapies. For ALL, concurrent use of other chemotherapy
Age Restrictions	Pediatric patients under 18 years of age
Prescriber Restrictions	For ALL, prescribed by or in consultation with an oncologist. For pJIA, prescribed by or in consultation with a rheumatologist
Coverage Duration	12 months
Other Criteria	For ALL, Xatmep is used as part of a combination chemotherapy maintenance regimen. For pJIA, patient had an insufficient response or intolerance to first-line therapy, including full-dose NSAIDs. Part B versus Part D determination will be made at time of prior authorization review per CMS guidance to establish if the drug prescribed is for a cancer diagnosis.

ConnectiCare

XELJANZ

Products Affected

- Xeljanz
- Xeljanz XR

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use with a biologic for an inflammatory condition (eg, tocilizumab, anakinra, abatacept, rituximab, certolizumab pegol, etanercept, adalimumab, infliximab, golimumab). Concurrent use with potent immunosuppressants that are not methotrexate (MTX) [eg, azathioprine, tacrolimus, cyclosporine, mycophenolate mofetil].
Required Medical Information	Diagnosis, concurrent medications, previous therapies tried.
Age Restrictions	18 years and older
Prescriber Restrictions	For Rheumatoid arthritis (RA), must be prescribed by or in consultation with a rheumatologist. For Psoriatic Arthritis (PsA), must be prescribed by, or in consultation with, a dermatologist or rheumatologist.
Coverage Duration	12 months
Other Criteria	For RA, patient has tried one conventional synthetic DMARD for at least 3 months. Patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD.

ConnectiCare

XERMELO

Products Affected

- Xermelo

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Treatment naive patients, use as a monotherapy
Required Medical Information	Diagnosis, previous therapies tried with dates of treatment, chart notes documenting number of bowel movements per day
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an oncologist or gastroenterologist
Coverage Duration	Initiation - 12 weeks, Continuation - 12 months
Other Criteria	For initiation for carcinoid sydrome diarrhea, the patient has been on a long-acting somatostatin analog (SSA) therapy (e.g. Somatuline Depot [lanreotide for injection], Sandostatin LAR Depot [octreotide for injection], octreotide injection) for at least 3 consecutive months and while on long-acting somatostatin analog therapy (prior to starting Xermelo) the patient continues to have at least four bowel movements per day and iii. Xermelo will be used in combination with a long-acting somatostatin analog therapy. For continuation for carcinoid sydrome diarrhea, the patient has experienced a decrease in the number of bowel movements per day and the patient continues to take Xermelo in combination with a long-acting somatostatin analog therapy.

ConnectiCare

XOLAIR

Products Affected

- Xolair subcutaneous recon soln

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Body weight greater than 150 kg.
Required Medical Information	For IgE-mediated allergic asthma: for patients 12 years of age and older, pre-treatment serum IgE level greater than or equal to 30 IU/mL to less than or equal to 700 IU/mL and patient's body weight. For IgE-mediated allergic asthma: for patients 6 to less than 12 years of age, pre-treatment serum IgE level greater than or equal to 30 IU/mL to less than or equal to 1,300 IU/mL and patient's body weight. For CIU - must have urticaria for more than 6 weeks, with symptoms present more than 3 days per week despite daily non-sedating H1-antihistamine therapy (e.g., cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine) AND must have tried therapy with a leukotriene modifier (e.g., montelukast) with a daily non-sedating H1 antihistamine.
Age Restrictions	6 years of age and older
Prescriber Restrictions	Moderate to severe persistent asthma if prescribed by, or in consultation with an allergist, immunologist, or pulmonologist. CIU if prescribed by or in consultation with an allergist, immunologist, or dermatologist.
Coverage Duration	12 months
Other Criteria	Moderate to severe persistent asthma must meet all criteria patient's asthma symptoms have not been adequately controlled by concomitant use of at least 3 months of inhaled corticosteroid and a long-acting beta-agonist (LABA) or LABA alternative, if LABA contraindicated or patient has intolerance then alternatives include sustained-release theophylline or a leukotriene modifier (eg, montelukast), AND inadequate control demonstrated by hospitalization for asthma, requirement for systemic corticosteroids to control asthma exacerbation(s), or increasing need (eg, more than 4 times a day) for short-acting inhaled beta2 agonists for symptoms (excluding preventative use for exercise-induced asthma).

ConnectiCare

XTANDI

Products Affected

- Xtandi

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Xtandi for a Covered Use.
Exclusion Criteria	Pregnancy
Required Medical Information	Documentation from medical records of diagnosis. For metastatic castration-resistant prostate cancer, prior therapies tried.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For prostate cancer, patient must have metastatic, castration-resistant prostate cancer for approval. The patient must have a history of failure, intolerance or contraindication to Zytiga before Xtandi is authorized.

ConnectiCare

YONSA

Products Affected

- Yonsa

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Pediatric patients less than 18 years of age
Required Medical Information	Documentation from medical records of diagnosis. For metastatic castration-resistant prostate cancer, prior therapies tried.
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For prostate cancer, patient must have metastatic, castration-resistant prostate cancer for approval. The patient is taking Yonsa in combination with methylprednisolone. The patient must have a history of failure, intolerance or contraindication to Zytiga before Yonsa is authorized.

ConnectiCare

ZEJULA

Products Affected

- Zejula

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, confirmed complete or partial response to platinum-based chemotherapy
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	For ovarian cancer, patient has had a complete or partial response to platinum-based chemotherapy AND Zejula therapy is to begin within 8 weeks after the most recent platinum-containing regimen

ConnectiCare

ZELBORAF

Products Affected

- Zelboraf

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus, patients with melanoma already started on vemurafenib.
Exclusion Criteria	N/A
Required Medical Information	For the FDA-approved indication of melanoma, for patients new to therapy, BRAFV600E status required.
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist or Hematologist
Coverage Duration	12 months
Other Criteria	Melanoma, patient new to therapy must have BRAFV600E mutation for approval.

ConnectiCare

ZYDELIG

Products Affected

- Zydelig

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Documentation of AST/ALT less than 20 x ULN and Bilirubin less than 10 x ULN, history of previous therapies tried
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For relapsed chronic lymphoid leukemia, Zydelig must be used in combination with rituximab. For Follicular, B-cell, relapsed Non-Hodgkin's lymphoma, patient must have previous history of at least 2 prior therapies. For relapsed small lymphocytic lymphoma, patient must have previous history of at least 2 prior therapies.

ConnectiCare

ZYKADIA

Products Affected
- Zykadia

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	12 months
Other Criteria	For metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive, patient must have progressed or be intolerant to crizotinib for approval.

ConnectiCare

PART B VERSUS PART D

Products Affected

- Abelcet intravenous suspension
- acetylcysteine solution
- acyclovir sodium intravenous solution
- albuterol sulfate inhalation solution for nebulization 0.63 mg/3 mL, 1.25 mg/3 mL, 2.5 mg /3 mL (0.083 %), 5 mg/mL
- AmBisome intravenous suspension for reconstitution
- amikacin injection solution 500 mg/2 mL
- Aminosyn 8.5 %-electrolytes intravenous parenteral solution
- Aminosyn II 10 % intravenous parenteral solution
- Aminosyn II 15 % intravenous parenteral solution
- Aminosyn II 8.5 % intravenous parenteral solution
- Aminosyn II 8.5 %-electrolytes intravenous parenteral solution
- Aminosyn-HBC 7% intravenous parenteral solution
- Aminosyn-PF 10 % intravenous parenteral solution
- Aminosyn-PF 7 % Sulfite Free intravenous parenteral solution
- Aminosyn-RF 5.2 % intravenous parenteral solution
- amphotericin B injection recon soln
- ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg
- ampicillin-sulbactam injection recon soln
- aprepitant oral capsule
- aprepitant oral capsule,dose pack
- Aralast NP intravenous recon soln 1,000 mg
- Astagraf XL oral capsule,extended release 24hr
- Azasan oral tablet
- azathioprine oral tablet
- azithromycin intravenous recon soln
- BCG vaccine, live (PF) percutaneous suspension for reconstitution
- budesonide inhalation suspension for nebulization 0.25 mg/2 mL, 0.5 mg/2 mL, 1 mg/2 mL
- calcitriol oral capsule
- calcitriol oral solution
- caspofungin intravenous recon soln
- cefazolin injection recon soln 1 gram, 10 gram, 500 mg
- cefepime injection recon soln
- cefoxitin intravenous recon soln
- ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg
- cefuroxime sodium injection recon soln 750 mg
- cefuroxime sodium intravenous recon soln
- clindamycin phosphate injection solution
- clindamycin phosphate intravenous solution 600 mg/4 mL
- CLINIMIX 5%/D15W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION
- Clinimix 5%/D25W sulfite free intravenous parenteral solution
- Clinimix 2.75%/D5W Sulfite Free intravenous parenteral solution
- Clinimix 4.25%/D10W Sulfite Free intravenous parenteral solution
- Clinimix 4.25%/D5W Sulfite Free intravenous parenteral solution
- Clinimix 4.25%-D20W Sulfite Free intravenous parenteral solution
- Clinimix 4.25%-D25W Sulfite Free intravenous parenteral solution
- Clinimix 5%-D20W Sulfite Free intravenous parenteral solution
- Clinimix E 2.75%/D10W Sulfite Free intravenous parenteral solution
- Clinimix E 2.75%/D5W Sulfite Free intravenous parenteral solution
- Clinimix E 4.25%/D10W Sulfite Free intravenous parenteral solution
- Clinimix E 4.25%/D25W Sulfite Free intravenous parenteral solution

- Clinimix E 4.25%/D5W Sulfite Free intravenous parenteral solution
- Clinimix E 5%/D15W Sulfite Free intravenous parenteral solution
- Clinimix E 5%/D20W Sulfite Free intravenous parenteral solution
- Clinimix E 5%/D25W Sulfite Free intravenous parenteral solution
- colistin (colistimethate Na) injection recon soln
- cromolyn inhalation solution for nebulization
- cyclophosphamide oral capsule
- cyclosporine modified oral capsule
- cyclosporine modified oral solution
- cyclosporine oral capsule
- D2.5 %-0.45 % sodium chloride intravenous parenteral solution
- D5 % and 0.9 % sodium chloride intravenous parenteral solution
- D5 %-0.45 % sodium chloride intravenous parenteral solution
- Depo-Provera intramuscular suspension 400 mg/mL
- dextrose 10 % and 0.2 % NaCl intravenous parenteral solution
- dextrose 10 % in water (D10W) intravenous parenteral solution
- dextrose 5 % in water (D5W) intravenous parenteral solution
- dextrose 5%-0.2 % sod chloride intravenous parenteral solution
- dextrose 5%-0.3 % sod.chloride intravenous parenteral solution
- Dextrose With Sodium Chloride intravenous parenteral solution
- dronabinol oral capsule
- Duramorph (PF) injection solution 0.5 mg/mL, 1 mg/mL
- Emend oral suspension for reconstitution
- Engerix-B (PF) intramuscular syringe
- Engerix-B Pediatric (PF) intramuscular syringe
- Envarsus XR oral tablet extended release 24 hr
- Erythrocin intravenous recon soln 500 mg
- fluconazole in NaCl (iso-osm) intravenous piggyback 200 mg/100 mL, 400 mg/200 mL
- furosemide injection syringe
- Gammagard S-D (IgA < 1 mcg/mL) intravenous recon soln
- Gengraf oral capsule 100 mg, 25 mg
- Gengraf oral solution
- gentamicin injection solution 40 mg/mL
- granisetron HCl oral tablet
- heparin (porcine) injection solution
- Hepatamine 8% intravenous parenteral solution
- hydromorphone (PF) injection solution 10 (mg/mL) (5 ml), 10 mg/mL
- imipenem-cilastatin intravenous recon soln
- Increlex subcutaneous solution
- Intralipid intravenous emulsion 20 %
- Intralipid intravenous emulsion 30 %
- Intron A injection recon soln
- Intron A injection solution
- ipratropium bromide inhalation solution
- ipratropium-albuterol inhalation solution for nebulization
- levalbuterol HCl inhalation solution for nebulization 0.31 mg/3 mL, 0.63 mg/3 mL, 1.25 mg/0.5 mL, 1.25 mg/3 mL
- levocarnitine (with sugar) oral solution
- levocarnitine oral tablet
- levofloxacin intravenous solution
- magnesium sulfate injection solution
- magnesium sulfate injection syringe
- meropenem intravenous recon soln
- methotrexate sodium (PF) injection solution
- methotrexate sodium injection solution
- methotrexate sodium oral tablet
- morphine injection syringe 10 mg/mL, 8 mg/mL
- moxifloxacin in NaCl (iso-osm) intravenous piggyback
- mycophenolate mofetil oral capsule
- mycophenolate mofetil oral suspension for reconstitution
- mycophenolate mofetil oral tablet

ConnectiCare

- mycophenolate sodium oral tablet,delayed release (DR/EC)
- nafcillin injection recon soln 1 gram, 10 gram
- Nebupent inhalation recon soln
- Nephramine 5.4 % intravenous parenteral solution
- Normosol-M in 5 % dextrose intravenous parenteral solution
- Normosol-R in 5 % dextrose intravenous parenteral solution
- Normosol-R pH 7.4 intravenous parenteral solution
- ondansetron HCl oral solution
- ondansetron HCl oral tablet
- ondansetron oral tablet,disintegrating
- paricalcitol oral capsule
- penicillin G potassium injection recon soln 20 million unit
- penicillin G sodium injection recon soln
- Pentam injection recon soln
- Perforomist inhalation solution for nebulization
- piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram
- Plasma-Lyte 148 intravenous parenteral solution
- Plasma-Lyte A intravenous parenteral solution
- Plenamine intravenous parenteral solution
- potassium chlorid-D5-0.45%NaCl intravenous parenteral solution
- potassium chloride in 0.9%NaCl intravenous parenteral solution 20 mEq/L, 40 mEq/L
- potassium chloride in 5 % dex intravenous parenteral solution 20 mEq/L, 40 mEq/L
- potassium chloride in LR-D5 intravenous parenteral solution 20 mEq/L
- potassium chloride-D5-0.2%NaCl intravenous parenteral solution 20 mEq/L
- potassium chloride-D5-0.3%NaCl intravenous parenteral solution 20 mEq/L
- potassium chloride-D5-0.9%NaCl intravenous parenteral solution
- Premasol 10 % intravenous parenteral solution
- Premasol 6 % intravenous parenteral solution
- Procalamine 3% intravenous parenteral solution
- Prosol 20 % intravenous parenteral solution
- Pulmozyme inhalation solution
- Rapamune oral solution
- Recombivax HB (PF) intramuscular suspension 10 mcg/mL, 40 mcg/mL
- Recombivax HB (PF) intramuscular syringe
- rifampin intravenous recon soln
- Sandimmune oral solution
- Sensipar oral tablet 30 mg, 60 mg, 90 mg
- sirolimus oral tablet
- Somatuline Depot subcutaneous syringe
- Somavert subcutaneous recon soln
- streptomycin intramuscular recon soln
- Synribo subcutaneous recon soln
- tacrolimus oral capsule
- Teflaro intravenous recon soln
- testosterone cypionate intramuscular oil
- testosterone enanthate intramuscular oil
- tetanus-diphtheria toxoids-Td intramuscular suspension
- tobramycin in 0.225 % NaCl inhalation solution for nebulization
- tobramycin sulfate injection solution
- Travasol 10 % intravenous parenteral solution
- Trelstar intramuscular syringe
- TrophAmine 10 % intravenous parenteral solution
- Trophamine 6% intravenous parenteral solution
- Twinrix (PF) intramuscular syringe
- vancomycin intravenous recon soln 1,000 mg, 10 gram, 500 mg
- Varubi oral tablet
- voriconazole intravenous solution
- Xgeva subcutaneous solution
- Zortress oral tablet 0.25 mg, 0.5 mg, 0.75 mg

Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

ConnectiCare

Index

A

Abelcet intravenous suspension 174
acetylcysteine solution 174
Acthar H.P... 1
Actimmune.. 2
acyclovir sodium intravenous solution ... 174
adapalene topical cream 155
adapalene topical gel 155
Adcirca 3
Adempas 4
Afinitor.. 5
Afinitor Disperz 5
albuterol sulfate inhalation solution for nebulization 0.63 mg/3 mL, 1.25 mg/3 mL, 2.5 mg /3 mL (0.083 %), 5 mg/mL 174
Alecensa 6
alosetron 7
alprazolam oral tablet extended release 24 hr 57
Alunbrig oral tablet 180 mg, 30 mg, 90 mg 8
Alunbrig oral tablets,dose pack.................. 8
AmBisome intravenous suspension for reconstitution..................................... 174
amikacin injection solution 500 mg/2 mL 174
Aminosyn 8.5 %-electrolytes intravenous parenteral solution............................. 174
Aminosyn II 10 % intravenous parenteral solution... 174
Aminosyn II 15 % intravenous parenteral solution... 174
Aminosyn II 8.5 % intravenous parenteral solution... 174
Aminosyn II 8.5 %-electrolytes intravenous parenteral solution............................. 174
Aminosyn-HBC 7% intravenous parenteral solution... 174
Aminosyn-PF 10 % intravenous parenteral solution... 174
Aminosyn-PF 7 % Sulfite Free intravenous parenteral solution............................. 174
Aminosyn-RF 5.2 % intravenous parenteral solution... 174
amitriptyline 59
amphotericin B injection recon soln 174
ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg 174
ampicillin-sulbactam injection recon soln 174
Ampyra 9
Anadrol-50 10
APOKYN 12
aprepitant oral capsule 174
aprepitant oral capsule,dose pack 174
Aptiom 13
Aralast NP intravenous recon soln 1,000 mg 174
Arcalyst 14
Astagraf XL oral capsule,extended release 24hr 174
Auryxia 15
Avonex (with albumin)............................ 16
Avonex intramuscular pen injector kit...... 16
Avonex intramuscular syringe kit 16
Azasan oral tablet.................................. 174
azathioprine oral tablet........................... 174
azithromycin intravenous recon soln 174

B

Banzel 17
BCG vaccine, live (PF) percutaneous suspension for reconstitution 174
Benlysta subcutaneous 18
benztropine oral 56
Betaseron subcutaneous kit....................... 19
bexarotene 20
Bosulif... 21
Briviact oral 22
budesonide inhalation suspension for nebulization 0.25 mg/2 mL, 0.5 mg/2 mL, 1 mg/2 mL... 174
butalbital-acetaminop-caf-cod 56
butalbital-acetaminophen oral tablet 50-325 mg 56
butalbital-acetaminophen-caff oral capsule 56
butalbital-acetaminophen-caff oral tablet 50-325-40 mg 56

butalbital-aspirin-caffeine oral capsule..... 56
C
Cabometyx 23
calcitriol oral capsule 174
calcitriol oral solution 174
Calquence.. 24
caspofungin intravenous recon soln........ 174
cefazolin injection recon soln 1 gram, 10 gram, 500 mg 174
cefepime injection recon soln 174
cefoxitin intravenous recon soln 174
ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg........... 174
cefuroxime sodium injection recon soln 750 mg 174
cefuroxime sodium intravenous recon soln 174
Cholbam.. 25
Cialis oral tablet 2.5 mg, 5 mg................. 26
Cinryze.. 27
clemastine oral tablet 2.68 mg 56
clindamycin phosphate injection solution174
clindamycin phosphate intravenous solution 600 mg/4 mL..................................... 174
Clinimix 5%/D25W sulfite free intravenous parenteral solution.............................. 174
Clinimix 2.75%/D5W Sulfite Free intravenous parenteral solution........... 174
Clinimix 4.25%/D10W Sulfite Free intravenous parenteral solution........... 174
Clinimix 4.25%/D5W Sulfite Free intravenous parenteral solution........... 174
Clinimix 4.25%-D20W Sulfite Free intravenous parenteral solution........... 174
Clinimix 4.25%-D25W Sulfite Free intravenous parenteral solution........... 174
CLINIMIX 5%/D15W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION....................................... 174
Clinimix 5%-D20W Sulfite Free intravenous parenteral solution.............................. 174
Clinimix E 2.75%/D10W Sulfite Free intravenous parenteral solution........... 174
Clinimix E 2.75%/D5W Sulfite Free intravenous parenteral solution........... 174
Clinimix E 4.25%/D10W Sulfite Free intravenous parenteral solution........... 174
Clinimix E 4.25%/D25W Sulfite Free intravenous parenteral solution........... 174
Clinimix E 4.25%/D5W Sulfite Free intravenous parenteral solution........... 175
Clinimix E 5%/D15W Sulfite Free intravenous parenteral solution........... 175
Clinimix E 5%/D20W Sulfite Free intravenous parenteral solution........... 175
Clinimix E 5%/D25W Sulfite Free intravenous parenteral solution........... 175
clomipramine 59
clonazepam oral tablet,disintegrating 58
clorazepate dipotassium 58
colistin (colistimethate Na) injection recon soln 175
Cometriq 28
Corlanor 29
Cosentyx (2 Syringes).............................. 30
Cosentyx Pen (2 Pens) 30
Cotellic.. 31
Crinone.. 32
cromolyn inhalation solution for nebulization....................................... 175
Cuprimine 114
cyclobenzaprine oral tablet 56
cyclophosphamide oral capsule 175
cyclosporine modified oral capsule 175
cyclosporine modified oral solution........ 175
cyclosporine oral capsule 175
cyproheptadine... 56
D
D2.5 %-0.45 % sodium chloride intravenous parenteral solution.............................. 175
D5 % and 0.9 % sodium chloride intravenous parenteral solution........... 175
D5 %-0.45 % sodium chloride intravenous parenteral solution.............................. 175
Daraprim 33
Demser 34
Depen Titratabs 114
Depo-Provera intramuscular suspension 400 mg/mL... 175
dextrose 10 % and 0.2 % NaCl intravenous parenteral solution.............................. 175

dextrose 10 % in water (D10W) intravenous parenteral solution............................ 175
dextrose 5 % in water (D5W) intravenous parenteral solution............................ 175
dextrose 5%-0.2 % sod chloride intravenous parenteral solution............................ 175
dextrose 5%-0.3 % sod.chloride intravenous parenteral solution............................ 175
Dextrose With Sodium Chloride intravenous parenteral solution............................ 175
Diazepam Intensol 58
diazepam oral solution 5 mg/5 mL (1 mg/mL) 58
diazepam oral tablet 58
diclofenac sodium topical gel 3 % 35
Digitek... 36
Digox... 36
digoxin oral solution 50 mcg/mL............. 36
digoxin oral tablet 36
doxepin oral 59
dronabinol oral capsule 175
Dupixent subcutaneous syringe 300 mg/2 mL 37
Duramorph (PF) injection solution 0.5 mg/mL, 1 mg/mL 175
E
Egrifta subcutaneous recon soln 1 mg 38
Eligard.. 84
Eligard (3 month).................................... 84
Eligard (4 month).................................... 84
Eligard (6 month).................................... 84
Emend oral suspension for reconstitution175
Enbrel subcutaneous recon soln................ 39
Enbrel subcutaneous syringe 25 mg/0.5mL (0.51), 50 mg/mL (0.98 mL)................ 39
Enbrel SureClick 39
Endari 40
Engerix-B (PF) intramuscular syringe 175
Engerix-B Pediatric (PF) intramuscular syringe 175
Envarsus XR oral tablet extended release 24 hr 175
Epclusa 41
ergoloid 56
Erivedge 42
Erleada 43
Erythrocin intravenous recon soln 500 mg 175
Esbriet 44
estradiol oral.. 59
Extavia subcutaneous kit.......................... 45
F
Farydak 46
fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg 152
fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr 154
Ferriprox oral tablet 47
Firazyr 48
fluconazole in NaCl (iso-osm) intravenous piggyback 200 mg/100 mL, 400 mg/200 mL 175
furosemide injection syringe.................. 175
Fycompa oral suspension 49
Fycompa oral tablet.................................. 49
G
Gammagard Liquid 70
Gammagard S-D (IgA < 1 mcg/mL) intravenous recon soln 175
Gamunex-C injection solution 1 gram/10 mL (10 %) 70
Gattex 30-Vial... 50
Gengraf oral capsule 100 mg, 25 mg 175
Gengraf oral solution 175
gentamicin injection solution 40 mg/mL 175
Gilotrif.. 51
glatiramer 52
Glatopa 52
granisetron HCl oral tablet...................... 175
H
Harvoni 54
heparin (porcine) injection solution 175
Hepatamine 8% intravenous parenteral solution.. 175
Hetlioz.. 55
Humira 60
Humira Pediatric Crohn's Start subcutaneous syringe kit 40 mg/0.8 mL, 40 mg/0.8 mL (6 pack), 80 mg/0.8 mL, 80 mg/0.8 mL-40 mg/0.4 mL....................................... 60

Humira Pen 60
Humira Pen Crohn's-UC-HS Start subcutaneous pen injector kit 40 mg/0.8 mL, 80 mg/0.8 mL 60
Humira Pen Psoriasis-Uveitis subcutaneous pen injector kit 40 mg/0.8 mL, 80 mg/0.8 mL-40 mg/0.4 mL.............................. 60
hydromorphone (PF) injection solution 10 (mg/mL) (5 ml), 10 mg/mL 175

I

Ibrance.. 62
Iclusig... 63
Idhifa.. 64
imatinib oral tablet 100 mg, 400 mg......... 65
Imbruvica 66
imipenem-cilastatin intravenous recon soln 175
imipramine HCl 59
imipramine pamoate................................ 59
Increlex subcutaneous solution............... 175
Ingrezza.. 67
Inlyta 68
Intralipid intravenous emulsion 20 % 175
Intralipid intravenous emulsion 30 % 175
Intron A injection recon soln 175
Intron A injection solution..................... 175
ipratropium bromide inhalation solution 175
ipratropium-albuterol inhalation solution for nebulization...................................... 175
Iressa 69

J

Jakafi oral tablet 10 mg, 15 mg, 20 mg, 25 mg, 5 mg 71
Juxtapid.. 72
Jynarque 73

K

Kadian oral capsule,extend.release pellets 200 mg 87
Kalydeco 74
Keveyis 75
Kisqali Femara Co-Pack oral tablet 200 mg/day(200 mg x 1)-2.5 mg, 400 mg/day(200 mg x 2)-2.5 mg, 600 mg/day(200 mg x 3)-2.5 mg 77
Kisqali oral tablet 200 mg/day (200 mg x 1), 400 mg/day (200 mg x 2), 600 mg/day (200 mg x 3)... 77
Korlym 78
Kuvan oral tablet,soluble 79
Kynamro 80

L

Lanoxin oral tablet 125 mcg, 250 mcg, 62.5 mcg.. 36
Lenvima oral capsule 10 mg/day (10 mg x 1), 14 mg/day(10 mg x 1-4 mg x 1), 18 mg/day (10 mg x 1-4 mg x2), 20 mg/day (10 mg x 2), 24 mg/day(10 mg x 2-4 mg x 1), 8 mg/day (4 mg x 2) 81
Letairis 82
Leukine injection recon soln.................... 83
leuprolide subcutaneous kit...................... 84
levalbuterol HCl inhalation solution for nebulization 0.31 mg/3 mL, 0.63 mg/3 mL, 1.25 mg/0.5 mL, 1.25 mg/3 mL .. 175
levocarnitine (with sugar) oral solution .. 175
levocarnitine oral tablet.......................... 175
levofloxacin intravenous solution........... 175
lidocaine topical adhesive patch,medicated 85
linezolid.. 86
linezolid in dextrose 5%.......................... 86
Lonsurf 89
lorazepam oral... 57
Lupron Depot.. 84
Lupron Depot (3 month) 84
Lupron Depot (4 month) 84
Lupron Depot (6 Month).......................... 84
Lynparza 90

M

magnesium sulfate injection solution...... 175
magnesium sulfate injection syringe....... 175
megestrol oral suspension 400 mg/10 mL (40 mg/mL), 625 mg/5 mL 91
megestrol oral tablet................................ 59
Mekinist 92
memantine oral capsule,sprinkle,ER 24hr 93
memantine oral solution........................... 93
memantine oral tablet............................... 93
memantine oral tablets,dose pack 93
meprobamate... 56

meropenem intravenous recon soln 175
metaxalone 56
methadone oral solution 10 mg/5 mL, 5 mg/5 mL 87
methadone oral tablet 10 mg, 5 mg........... 87
methamphetamine 94
methotrexate sodium (PF) injection solution 175
methotrexate sodium injection solution .. 175
methotrexate sodium oral tablet............. 175
methyldopa-hydrochlorothiazide 56
modafinil 95
morphine injection syringe 10 mg/mL, 8 mg/mL... 175
morphine oral capsule, ER multiphase 24 hr 120 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg 87
morphine oral capsule,extend.release pellets 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg 87
morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg 87
moxifloxacin in NaCl (iso-osm) intravenous piggyback... 175
mycophenolate mofetil oral capsule 175
mycophenolate mofetil oral suspension for reconstitution...................................... 175
mycophenolate mofetil oral tablet 175
mycophenolate sodium oral tablet,delayed release (DR/EC) 176

N

nafcillin injection recon soln 1 gram, 10 gram 176
Natpara 96
Nebupent inhalation recon soln 176
Nephramine 5.4 % intravenous parenteral solution... 176
Nerlynx 97
Neupogen 98
Neupro... 99
Nexavar 100
Ninlaro 101
Norditropin FlexPro 53
Normosol-M in 5 % dextrose intravenous parenteral solution.............................. 176
Normosol-R in 5 % dextrose intravenous parenteral solution.............................. 176
Normosol-R pH 7.4 intravenous parenteral solution... 176
Northera 102
Nuedexta 103
Nuplazid oral tablet 17 mg...................... 104

O

octreotide acetate injection solution........ 105
Odomzo 106
Ofev... 107
ondansetron HCl oral solution 176
ondansetron HCl oral tablet 176
ondansetron oral tablet,disintegrating 176
Onfi oral suspension 108
Onfi oral tablet 10 mg, 20 mg 108
Opsumit 109
Orencia ClickJect 110
Orencia subcutaneous syringe 125 mg/mL, 50 mg/0.4 mL, 87.5 mg/0.7 mL 110
Orkambi oral tablet 111
Otezla 112
Otezla Starter oral tablets,dose pack 10 mg (4)-20 mg (4)-30 mg (47)................... 112
oxazepam 57
oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg 87

P

paricalcitol oral capsule 176
Pegasys subcutaneous solution 113
Pegasys subcutaneous syringe 113
penicillin G potassium injection recon soln 20 million unit................................... 176
penicillin G sodium injection recon soln 176
Pentam injection recon soln 176
Perforomist inhalation solution for nebulization....................................... 176
perphenazine-amitriptyline 59
phenobarbital... 59
phenoxybenzamine 115
piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram 176
Plasma-Lyte 148 intravenous parenteral solution.. 176

ConnectiCare

Plasma-Lyte A intravenous parenteral solution ... 176
Plegridy subcutaneous pen injector 125 mcg/0.5 mL, 63 mcg/0.5 mL- 94 mcg/0.5 mL ... 116
Plegridy subcutaneous syringe 125 mcg/0.5 mL, 63 mcg/0.5 mL- 94 mcg/0.5 mL.. 116
Plenamine intravenous parenteral solution ... 176
Pomalyst ... 117
potassium chlorid-D5-0.45%NaCl intravenous parenteral solution ... 176
potassium chloride in 0.9%NaCl intravenous parenteral solution 20 mEq/L, 40 mEq/L ... 176
potassium chloride in 5 % dex intravenous parenteral solution 20 mEq/L, 40 mEq/L ... 176
potassium chloride in LR-D5 intravenous parenteral solution 20 mEq/L ... 176
potassium chloride-D5-0.2%NaCl intravenous parenteral solution 20 mEq/L ... 176
potassium chloride-D5-0.3%NaCl intravenous parenteral solution 20 mEq/L ... 176
potassium chloride-D5-0.9%NaCl intravenous parenteral solution ... 176
Praluent Pen subcutaneous pen injector 150 mg/mL, 75 mg/mL ... 118
Premasol 10 % intravenous parenteral solution ... 176
Premasol 6 % intravenous parenteral solution ... 176
Prevymis oral ... 120
Procalamine 3% intravenous parenteral solution ... 176
Procrit injection solution 10,000 unit/mL, 2,000 unit/mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL, 40,000 unit/mL ... 121
Prolia ... 123
Promacta ... 125
promethazine oral tablet ... 56
Prosol 20 % intravenous parenteral solution ... 176
Pulmozyme inhalation solution ... 176

Q

quinine sulfate ... 126

R

Rapamune oral solution ... 176
Ravicti ... 127
Rebif (with albumin) ... 128
Rebif Rebidose subcutaneous pen injector 22 mcg/0.5 mL, 44 mcg/0.5 mL, 8.8mcg/0.2mL-22 mcg/0.5mL (6) ... 128
Rebif Titration Pack ... 128
Recombivax HB (PF) intramuscular suspension 10 mcg/mL, 40 mcg/mL ... 176
Recombivax HB (PF) intramuscular syringe ... 176
Repatha ... 129
Repatha Pushtronex ... 129
Repatha SureClick ... 129
Revlimid ... 132
ribavirin oral capsule ... 133
ribavirin oral tablet 200 mg ... 133
rifampin intravenous recon soln ... 176
Rubraca ... 134
Rydapt ... 135

S

Sabril oral tablet ... 160
Samsca oral tablet 15 mg, 30 mg ... 136
Sandimmune oral solution ... 176
Sensipar oral tablet 30 mg, 60 mg, 90 mg ... 176
Signifor ... 137
sildenafil (Pulmonary Arterial Hypertension) oral ... 131
sirolimus oral tablet ... 176
Somatuline Depot subcutaneous syringe 176
Somavert subcutaneous recon soln ... 176
Sprycel oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg ... 138
Stelara subcutaneous ... 139
Stivarga ... 140
streptomycin intramuscular recon soln ... 176
Sutent ... 141
Sylatron ... 142
Symdeko ... 143
Synribo subcutaneous recon soln ... 176
Syprine ... 144

ConnectiCare

T
tacrolimus oral capsule ... 176
Tafinlar ... 145
Tagrisso ... 146
Tarceva oral tablet 100 mg, 150 mg, 25 mg ... 147
Tasigna ... 148
Teflaro intravenous recon soln ... 176
temazepam ... 57
testosterone cypionate intramuscular oil ... 176
testosterone enanthate intramuscular oil ... 176
tetanus-diphtheria toxoids-Td intramuscular suspension ... 176
tetrabenazine ... 149
Thalomid ... 150
thioridazine ... 151
tobramycin in 0.225 % NaCl inhalation solution for nebulization ... 176
tobramycin sulfate injection solution ... 176
topiramate oral capsule, sprinkle ... 11
topiramate oral capsule,sprinkle,ER 24hr ... 11
topiramate oral tablet ... 11
Tracleer oral tablet ... 153
Tracleer oral tablet for suspension ... 153
Travasol 10 % intravenous parenteral solution ... 176
Trelstar intramuscular syringe ... 176
tretinoin microspheres topical gel ... 155
tretinoin topical topical cream ... 155
tretinoin topical topical gel 0.01 %, 0.025 % ... 155
trientine ... 144
trihexyphenidyl ... 56
trimipramine ... 59
TrophAmine 10 % intravenous parenteral solution ... 176
Trophamine 6% intravenous parenteral solution ... 176
Twinrix (PF) intramuscular syringe ... 176
Tykerb ... 156
U
Uptravi oral tablet ... 157
Uptravi oral tablets,dose pack ... 157
V
vancomycin intravenous recon soln 1,000 mg, 10 gram, 500 mg ... 176
Varubi oral tablet ... 176
Venclexta ... 158
Venclexta Starting Pack ... 158
Verzenio ... 159
vigabatrin ... 160
Vimpat oral solution ... 161
Vimpat oral tablet ... 161
voriconazole intravenous solution ... 176
Votrient ... 162
X
Xalkori ... 163
Xatmep ... 164
Xeljanz ... 165
Xeljanz XR ... 165
Xermelo ... 166
Xgeva subcutaneous solution ... 176
Xolair subcutaneous recon soln ... 167
Xtandi ... 168
Y
Yonsa ... 169
Z
Zejula ... 170
Zelboraf ... 171
zonisamide ... 11
Zortress oral tablet 0.25 mg, 0.5 mg, 0.75 mg ... 176
Zydelig ... 172
Zykadia ... 173

ConnectiCare, Inc. is an HMO/HMO-POS plan with a Medicare contract. Enrollment in ConnectiCare depends on contract renewal.

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

Beneficiaries must use network pharmacies to access their premium and/or copayment/coinsurance may change on January 1, 2020.

This document includes ConnectiCare Medicare Plan's partial formulary as of October 9, 2018. For a complete, updated formulary, please visit our website at www.connecticare.com/Medicare or call the Member Services number below.

For alternative formats or language, please call Member Services toll free at:

1-800-CCI-CARE (1-800-224-2273) between the hours of 8:00 a.m. and 8:00 p.m., seven days a week.

TTY/TDD users should call 1-800-842-9710.

19197 v8